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Diabetes is a chronic metabolic disease which hampers the systemic glucose 
metabolism that results in hyperglycemic condition in the bloodstream due to 
defect in insulin secretion, insulin action or both. The effect of chronic 
hyperglycemia has been long term associated with vascular dysfunction and 
damage in various tissues and blood vessels. Endothelial cells (ECs) are 
monolayer of cells that cover the internal lumen of all blood vasculature and serve 
as an interface between circulating blood and surrounding tissues. But 
unfortunately, these endothelial cells in the blood vasculature damaged due to 
hyperglycemia could be identified in the later stage of the disease progression. 
Therefore, there is a need to identify the endothelial dysfunction in its early stage 
using potential biomarker. MicroRNAs (miRNAs) in the circulating blood could 
be the potential candidate to identify the endothelial dysfunction caused by 
hyperglycemia. The hypothesis for this project was proposed as fol1ows: 1) 
miRNAs could be a potential biomarker to differentiate the Impaired Fasting 
blood Glucose (IFG) and Type 2 Diabetes Mellitus (T2DM) from healthy 
individual. 2) miRNAs could able to response to the different glucose level and 
also possibly involves in the processes of endothelial dysfunction (apoptosis, 
hyperpermeability and senescence) in T2DM.  In order to differentiate IFG and 
T2DM, microRNA microarray data of patient’s blood samples were analyzed 
which showed that 178 miRNAs were dysregulated from the healthy individuals.  
ii 
 
The discriminative power of the study were improved by comparing the miRNA 
microarray data from rat model of T2DM and found 52 conserved miRNAs are 
consistent with diabetes condition in both species. To conduct further 
investigation on the roles of these miRNAs in diabetes, bioinformatics approach 
was taken and KEGG pathway analysis were carried out using both miRWalk 2.0 
and DIANA miRpath 2.0. Likewise the mRNA microarray analysis from human 
IFG and T2DM blood samples was also carried out to identify the genes involved 
in the disease progression. The combinations of miRNA and mRNA pathway 
analysis results showed that there are 10 common pathways were significantly 
dysregulated and potentially involve in vascular endothelial dysfunction. Human 
umbilical vein endothelial cells (HUVECs) were used as an in vitro model for 
hyperglycemia induced endothelial dysfunction. The miRNA microarray data 
analysis results from those studies showed that there are a total of 62 “glucose-
sensitive miRNAs” detected, showing increased expression with increasing 
glucose concentration at different time intervals (24 and 48 hrs). Among them, 10 
miRNAs (miR-26a-5p, miR-26b-5p, miR-29b-3p, miR-29c-3p, miR-125b-1-3p, 
miR-130b-3p, miR-140-5p, miR-192-5p, miR-221-3p and miR-320a) were 
commonly identified in human and rat model of T2DM. Of which, six miRNAs 
were found to be inversely correlated with anti-apoptotic genes (MCL1 and 
BCL2) expression. Hence these miRNAs could be potential biomarker to detect 
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1.1       Diabetes and its Prevalence  
Diabetes Mellitus (DM) is a complex metabolic disorder in which the body’s 
ability to utilize glucose is impaired and it is associated with defects in insulin 
secretion or insulin action on target tissues such as pancreas, liver, skeletal muscle 
and adipose tissue [1]. Insulin is required for the efficient metabolism of glucose 
by various tissues (Figure 1.1). DM is characterized by the impaired level of 
insulin or its action followed by chronic hyperglycemia (fasting blood glucose >7 
mmol/l or HbA1c >6.5%) in blood. The long-term exposure to high glucose 
steadily deteriorates various metabolically active organs such as heart, kidneys, 
eyes and blood vasculature [2]. Globally, DM is one of the most rapidly 
increasing non-communicable diseases (NCD) that has reached epidemic 
proportions and affecting 382 million people worldwide (Figure 1.2) among them 
80% live in low and middle income countries [2]. Furthermore, International 
Diabetic Federation (IDF) predicts that by 2035 the prevalence of DM is 
estimated to rise up to 592 million. The enormous financial burden of diabetes 
was invoked by 5.1 million deaths in 2013 all over the world. This means that 
every six seconds a person will be dying due to diabetes or diabetes related 
complications. The prevalence of diabetes in Singapore is no less overwhelming 
with 1 in 9 individuals between the ages of 20 to 79 being afflicted by diabetes. 
This accounts for about 12.8% of the population or over 533,600 cases with this 
metabolic disorder in 2014 [http://www.singstat.gov.sg/, 2]. The onset of diabetes 
often goes undetected until later stages where severe hyperglycemia causes injury 
to multiple organs by micro and macrovascular damages. Hence, there is an 
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urgency to identify the diabetic individuals well before the disease ensures and to 
maintain their glucose level.  
 
Figure 1.1: Glucose homeostasis. The maintenance of blood glucose in our body 
is mainly regulated by the interplay between two endocrine hormones secreted 
from the pancreas, namely insulin and glucagon. The figure adapted from IDF 
atlas 7
th






Figure 1.2: Prevalence of diabetes worldwide 2013. The diagrammatic 
representation shows the prevalence of diabetes cases worldwide (in millions) in 
2013 as well as projected figures for 2035. The figure adapted from IDF atlas 7
th
 




1.2       Types of Diabetes Mellitus 
There are two most important types of diabetes namely, Type 1 diabetes mellitus 
(T1DM), and Type 2 diabetes mellitus (T2DM) [3]. 
1.2.1    Type 1 diabetes mellitus (T1DM)  
T1DM is also known as juvenile onset diabetes, caused due to the autoimmune 
destruction of insulin-producing pancreatic β-cells by our own body’s defense 
mechanism and hence the body suffers from complete deficiency of insulin 
(Figure 1.3). The T1DM can affect all the age groups but usually occurs in 
children and young adults. Approximately 10% of diabetic populations are 
affected with T1DM [4]. Four major auto-immune antibodies which trigger 
inflammatory reactions against the pancreatic β-cells have been identified so far. 
They are: Glutamic acid decarboxylase 65 (GAD65), insulin autoantibodies (IAA), 
Zinc transporter 8 (ZnT8) and tyrosine phosphatase-like molecule. About 70% of 
patients with T1DM are GAD65 positive and the remainder is affected by anyone 
of the remaining autoantibodies mentioned above among the newly diagnosed 
T1DM individuals [5]. The T1DM patients often develop sudden symptoms such 
as abnormal thirsty with dry mouth, polyuria, giddiness, polyphagia, sudden 
weight loss, recurrent infections and blurred eye vision. The individuals with 
T1DM need lifetime administration of insulin on a daily basis and without insulin 






Figure 1.3: Type 1 diabetes mellitus. In healthy individuals, the normal islet 
having β-cells produce insulin to regulate the glucose homeostasis in the blood 
whereas in T1DM the autoimmunity develops against the β-cells and destroy 
them completely such that there is no insulin production (Adapted from 
http://info.superpharmacy.com.au/type-1-diabetes-mellitus-causes-of-diabetes/). 
T1DM is often linked with family history because of higher hereditary 
predisposition rate. Apart from that, genetic risk factors such as mutations in HLA 






1.2.2 Type 2 diabetes mellitus (T2DM) 
Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and it 
accounts for 85% cases of diabetes [2]. T2DM is both genetic and life style 
mediated metabolic disorder which occurs when the insufficient amount of insulin 
is produced by the pancreatic beta cells to maintain glucose homeostasis or the 
sensitivity of the target tissue is compromised such that they can no longer 
respond to the insulin and attain a state of “Insulin resistance”. In both insulin 
deficiency and insulin resistance, the blood glucose level could not be regulated 
and gets elevated in the body. Over the period of time, the excess of glucose 
(hyperglycemia) will undoubtedly increase the risk of developing diabetic related 
vascular complications [7, 8]. 
1.3      Risk factors of T2DM 
Several risk factors are known to be associated with T2DM. The risk factors could 
be classified into two major types, namely non-modifiable risk factors and 
modifiable risk factors (Figure 1.4). Non-modifiable risk factors include age, 
previous family history of diabetes, race/ethnicity, and history of gestational 
diabetes. Modifiable risk factors prone to T2DM are lack of physical activity, 
central obesity, hypertension, dyslipidemia, smoking, polycystic ovary syndrome 




Figure 1.4: Risk factors of T2DM. Type 2 diabetes mellitus (T2DM) results from 
a complex interaction of both non-modifiable and modifiable risk factors. 
1.4    Diagnosis of T2DM  
Hyperglycemia is the major causative factor for the onset of diabetes and 
progression of other diabetes related vascular complications. The only the current 
method to quantify level of elevated blood glucose in T2DM is by measuring 
plasma glucose (Impaired Fasting Glucose (IFG) and Oral Glucose Tolerance 
Test (OGTT) and Glycated hemoglobin (HbA1c) levels, which could only be 
useful to diagnose upon late stage of the disease (Table 1.1). Although the 
introduction of HbA1c level offers greater sensitivity and specificity for diabetes, 
their measurement in blood could fluctuate due to various factors such as 
erythropoiesis, genetic and chemical alterations in hemoglobin, 
hemoglobinopathies and drugs such as large dosage of aspirin [10].   
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More importantly, the measurement of HbA1c represents high glycation of 
proteins in the body and it is only a secondary event observed subsequently to the 
high blood glucose. Epidemiological studies showed that measurement of HbA1c 
level as a biomarker for diabetic related complications are not reliable [10]. 
Therefore, it is important to pay attention to the primary effects/responses of 
hyperglycemia. The dysregulation of glucose metabolism starts even before 
diabetes sets in shows the importance to study its effect in prediabetes stage itself.  
 HbA1c IFG OGTT 
(%) mg/dl mmol/l mg/dl mmol/l 
Diabetes >  6.5 ≥ 126   ≥ 7  ≥ 200  ≥ 11.1  
Prediabetes 5.7 – 6.4 100 - 125 > 5.6 - < 7.0 140 - 199 7.8 – 11 
Normal  <  5.6 <  99 < 6.1 <  139 <  7.72 
 
Table 1.1: Diagnosis of prediabetes and T2DM. Measurement of blood glucose 
level and HbA1c levels in blood/plasma. IFG =Impaired Fasting Glucose; OGTT- 
Oral Glucose Tolerance Test 
1.5   Prediabetes 
The term “prediabetes” describes an early stage of diabetes in which the glycemic 
parameters (glucose/HbA1c) are slightly elevated as compared to the healthy 
individuals (> 5.6 mmol/l) / ≥ 5.7%). A diabetic individual will have 
measurements of blood glucose level greater than 7.0 mmol/l and HbA1c level 
more than 6.5%. Prediabetes (Table 1.2) comprises of impaired glucose tolerance 
(IGT) or impaired fasting blood glucose (IGF) or both and the individuals who 
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fall under this category are likely to develop T2DM in near future [11, 12] unless 
controlled by diet and/or medications. Every year around 5-10% of individuals 
with prediabetes progress to T2DM and this progression varies from one 
population one another. 

























Table 1.2: Diagnostic values of glucose and HbA1c for prediabetes.  
The individuals with prediabetes are tested for their fasting blood glucose level or 
by oral glucose tolerant test (OGTT). IFG/IGT shares many characteristic features 
with T2DM and it is associated with central obesity (excessive abdominal fat), 
insulin resistance, and dyslipidemia (elevated low-density lipoprotein (LDL) and 
low levels of high-density lipoprotein (HDL)) [13]. International Diabetic 
Federation (IDF) reports that there are nearly about 348 million people have been 
identified with IGT and this is estimated to increase up to 471 million by 2035. It 
is known that nearly 70% of them will develop diabetes. Prediabetes is linked 
with increased risks of major vascular diseases. The human cohort study by 
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NHANES (National Health and Nutrition Examination Survey) in 1999-2006 
reported that individuals with prediabetes had increases the risk of vascular 
diseases such as diabetes nephropathy or retinopathy and cardiovascular diseases 
by 8 and 11% respectively [14-18]. Majority of these micro and macro vascular 
complications are due to impairment of endothelial cell function.  
1.6  Endothelial cells in peripheral tissue vasculature 
Healthy endothelial cells (EC) are a quiescent, flat and monolayer of cells that 
line the internal lumen of all vasculature and serve as an interface between 
circulating blood and vascular smooth muscle cells (VSMCs) [19]. In general, 
arterial ECs are thicker than those in veins, with the exception of high endothelial 
venules (HEVs), which have been described as plump and cuboidal [19]. On the 
other hand, venous ECs are short and wide, as blood flow rates in the venous 
circulation are significantly lower than the arterial circulation. Physiological 
venous and arterial shear stress levels are typically 1–5 dynes/cm2 and 10–40 
dynes/cm
2
, respectively [19].  The vascular endothelium in brain and retina are 
indistinguishable at the ultrastructural level and are composed of non-fenestrated 
EC with well-developed tight junctions. They confer a high degree of control of 
solute and fluid permeability. The liver, spleen and bone marrow sinusoids are 
lined by discontinuous EC to allow cellular trafficking between intercellular gaps. 
Most of the endocrine glands and kidney are lined by fenestrated or discontinuous 
EC that facilitate selective permeability of larger molecules such as protein 
through absorption, secretion, or filtration. The loss of EC barrier function in all 
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vasculature causes tumor invasion, angiogenesis, ischemic stroke, inflammation 
and cardiovascular diseases [20]. ECs adhere to one another through tight 
junctions (zona occludens) and adherens junctions (zona adherens). They 
communicate with neighboring cells through gap junctions also known as 
connexins, which act as channels for intercellular exchange of ions and small 
molecules [21]. The expression and organization of intercellular junctions vary 
throughout the vascular tree, corresponding to the site specific functional 
requirements of the specific vessels. Post-capillary venules, exhibit loosely or 
poorly organized tight junctions, whereas the intercellular junctions in arteries of 
all calibers are much tighter than those in veins [22]. Although arteries and veins 
both function as conduits and are lined by continuous non-fenestrated 
endothelium, the differences exist between the arterial and venous endothelium, 
with variation in both their size and shape across the vascular tree [23, 24]. Tight 
junctions form a continuous belt-like structure at the intercellular junctions in 
between apical and basolateral membrane which regulates paracellular transport 
across the endothelium. Tight junctions can function either as a `gate' which 
selectively allows the passage of ions, water, and various other macromolecules 
through the paracellular spaces or works as a `fence' to maintain the cell polarity 
and prevents mixing of molecules across the endothelial layer. Dysregulation of 
these functions is often associated with infectious diseases, cancer, cardiovascular 
disease and stroke [25]. VE-cadherin is the endothelial specific transmembrane 
component of adherens junction that is involved in the restriction of EC 
proliferation, acting as a mechanosensor of blood flow, and in cytoskeleton 
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organization [26]. The other adherens junction proteins such as PECAM, β-
catenin, endoglin transfer intercellular signals to modulate EC activation, 
permeability, and leukocyte infiltration [26]. Another important junctional 
complex in the endothelium that involved in the cell to cell communication with 
the neighboring cells is called connexin (Cx): Cx37, Cx40, and Cx43. Deficiency 
in gap junction proteins would lead to defects in coronary vasculogenesis and 
mutation in Cxs37 has been reported to promote atherogenesis and inflammatory 
diseases [27]. The dysfunctions of endothelial cell are regulated by various 
molecular signaling mechanisms and their causes are often multifactorial and not 
yet clearly understood.  
1.7  Functions of endothelial cell 
1.7.1  Transport of molecules 
The continuous endothelial lining of the blood vessels is an important barrier for 
the selective passage of plasma proteins, solutes, and fluid from the blood to the 
underlying interstitium and cells. Specific mechanisms transport essential 
circulating macromolecules across ECs to the subendothelial space to meet the 
metabolic needs of surrounding cells. There are two routes of transport across the 
endothelium: transcellular, by means of transcytosis, and paracellular through 
interendothelial junctions such as tight junctions and adherens junctions. 
Pathological process such as inflammation, atherogenesis, cancer, and stroke are 
often associated with the hyperpermeability across endothelium [25]. The 
endothelium also plays a vital role in the transport of nutrients across the barrier. 
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There are a total of eight facilitative glucose transporters (GLUT) supergene 
family but only GLUT-1 and GLUT-4 are expressed in ECs. The blood-brain 
barrier is the major endothelial tissue expressing GLUT-1 transporters [28]. 
However, glucose transporters are also expressed in ECs throughout the body, 
including the umbilical vein, adrenal capillaries, aorta, retina, heart, placenta, eye, 
and testis. Regulation of GLUT-4 expression is an essential process for glucose 
transport and is particularly important in disease progression of diabetes, and 
cardiovascular disease [29].  
1.7.2 Maintenance of vascular tone 
The EC is considered to be the largest endocrine organ in our body which 
responds to various humoral, neural and mechanical stimuli and secretes various 
autocrine as well as paracrine vasoactive agents to maintain the vascular tone 
[30]. Any changes in their homeostasis will result in vascular complications 
(Figure 1.5). In order to maintain the vascular tone, the EC produces various 
components of extracellular matrix such as collagen and some chemical mediators 
including nitric oxide (NO), endothelin – 1, angiotensin II (ANG-II), tissue-t AI-
1), von Willebrand factor (vWF), adhesion molecules (Vascular cell adhesion 
protein 1 (VCAM-1), Intercellular Adhesion Molecule 1 (ICAM), tissue 
plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PE-CAM) and 
cytokines such as Tumor Necrosis Factor α (TNFα) [31]. Nitric oxide (NO) is a 
smallest gas molecule with potent vasodilation activity regulates the vascular tone 
via a signaling molecule. NO is synthesized from its substrate L-arginine by the 
action of endothelial nitric oxide synthase with the help of molecular oxygen, 
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tetrahydrobiopterin (BH4), heme, nicotinamide adenine dinucleotide phosphate 
(NADPH), Flavin mononucleotide (FMN) as cofactors and calmodulin. The 
decrease in the NO production could lead to activation of the endothelial cell 
resulting in an increase in the platelet aggregation and inflammation and causing 
vascular dysfunction. Because of this, NO is being considered as potent treatment 
for various vascular related diseases such as stroke, diabetes, and atherosclerosis 
[32-34].  Endothelial cells also release other vasodilators in order to compensate 
the decrease in the NO bioavailability such as endothelium-derived 
hyperpolarizing factor (EDHF) and prostaglandin I₂ (PGI₂) [35, 36]. On the other 
hand, to balance these vasodilation factors (NO, EDHF, PGI2) endothelial cells 
produce vasoconstrictors such as endothelin – 1, angiotensin – II to maintain the 




Figure 1.5: Mechanism endothelial dysfunction in prediabetes and T2DM 
1.7.3  Host defense and inflammation  
ECs are in a unique strategic position for orchestrating immune and inflammatory 
responses. They secrete chemokines and cytokines to recruit neutrophils, natural 
killer cells, monocytes, macrophages, and T-lymphocytes at the site of 
inflammation or injury. ECs also express E-selection, P-selectin, intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule (VCAM). 
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Intercellular adhesion molecule-2 (ICAM-2) is constitutively expressed on resting 
ECs. ICAM-1 and VCAM are only minimally expressed on resting ECs, but their 
expression can be increased by cytokines and endotoxin (LPS) activation to 
regulate the EC leucocyte movement [39]. 
1.7.4  Homeostasis and coagulation   
EC plays a crucial role in the maintenance of homeostatic control of the blood 
vessels. ECs regulate the process of homeostasis by promoting anticoagulant 
factors such as thrombomodulin and protein C. However, when the ECs are 
activated by vasoactive agents such as thrombin, histamine, epinephrine (Potent 
inducers of procoagulant factor) induces vWF (procoagulant factor) and involved 
in the formation of thrombosis in blood vessels. Both infection and inflammatory 
processes can lead to elevation of plasma VWF [40]. ECs also produce 
ectonucleotidases, which are enzymes that dephosphorylate ADP to AMP then to 
adenosine, thereby inhibiting platelet aggregation [41]. 
1.8  Endothelial dysfunction in vascular complications of T2DM 
Two landmark studies from DCCT (Diabetes Control and Complications Trial) in 
1993 and UKPDS (United Kingdom Prospective Diabetes Study) in 1998 showed 
that hyperglycemia in blood could increase all forms of vascular complications in 
diabetes, particularly diabetic retinopathy, nephropathy, stroke and cardiovascular 
diseases (Figure 1.6) [42, 18]. The prolonged hyperglycemia in diabetes has also 




1.8.1  Endothelial dysfunction in macrovascular diseases 
1.8.1.1 Cardiovascular diseases (CVD) 
ECs in the heart play a variety of roles both during the development as well as in 
adult human and animal hearts [43-45]. The interactions between ECs and 
cardiomyocyte cell signaling plays a crucial role in the regulation of 
cardiovascular homeostasis by modulating cardiac functions such as 
contractibility, cardiomyocyte hypertrophy and also promote inflammation upon 
pathological conditions such as myocardial ischemia, diabetic cardiomyopathy 
and heart failure [46]. EC releases growth factors that act as an autocrine and 
paracrine factors during cellular stress (e.g. oxidative stress, hypoxia) in order to 
regulate the cardiac function back to normalcy [47, 48]. Recently Leucker et. al. 
[49], reported that the impairment of endothelial-cardiomyocyte interaction upon 
hyperglycemia induced oxidative stress increases the susceptibility of 
cardiomyocytes to ischemia and reperfusion injury. Despite this, Hedhli et. al, 
[50] showed that the EC-derived growth factor neuregulin (NRG) mediates the 
protective function of the heart against ischemic injury by inducing the 
angiogenesis and arteriogenesis. 
Atherosclerosis is a slow, but complex, multifactorial progressive disease in 
which an artery wall thickens and hardens due to the accumulation of fatty 
materials (cholesterol and triglycerides), cellular waste products, fibrin and 
calcium resulting in plaque formation and blood flow restriction. This arterial 
plaque can burst in later stages to cause a blood clot in the other regions of the 
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body such as the heart (heart attack) or brain (ischemic stroke) [51].  The 
endothelium maintains vascular homeostasis by releasing various mediators such 
as nitric oxide, prostacyclin and regulates platelet aggregation and thrombus 
formation [52]. However, due to various noxious stimuli the endothelial 
dysfunction occurs during the early process of atherogenesis and contributes to 
the formation of atherosclerotic plaque [52]. Recent studies have also documented 
the involvement of endothelial cells in atherogenesis and inflammation during of 
atherosclerosis [53, 54].  
1.8.1.2 Stroke 
Stroke is a complex disease with the multifaceted mechanism and is the fourth 
leading cause of death, after heart disease, cancer and chronic lower respiratory 
disease (CLRD; W.H.O) [55]. Every year, 15 million stroke incidences are 
reported worldwide. Of these, 5.5 million individuals die (3 million women and 
2.5 men) and another 5 million individuals are left with permanent disability 
which creates major familial, social and economic burden [55]. Along with the 
cerebrovascular disease, stroke accounts for 9.7% of all deaths [55]. The 
disability-adjusted life year (DALY) measures the global burden of disease and 
integrates the total amount of life lost from a disease process due to premature 
mortality and living with a disability [55]. W.H.O reported that the burden of 
stroke could rise from around 46.6 million in 2004 to 61 million DALYs in 2020 
[55].To date, the only approved treatment for ischemic stroke is the 
administration of recombinant tissue plasminogen activator (rtPA). However, this 
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treatment has a limited therapeutic window of 3 - 4.5 hours from the onset of 
stroke and hence minimizes its therapeutic usage [56]. The damage to the arterial 
EC and its dysfunction plays a crucial role in the stroke pathophysiology [57]. 
Endothelial activation upon ischemic injury characterized by increased expression 
of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1), P-selectin and E-selectin causes the change from an 
anticoagulant to a procoagulant state [58]. The loss of EC function has been 
reported as the primary step in stroke pathology, subsequently leads to the 
increased permeability of blood brain barrier (BBB) [58]. Breakdown of blood-
brain barrier is an important event that takes place during stroke pathology and it 
is due to partial or complete disruption of tight junction and adherens junction 







Figure 1.6: Organs affected due to diabetes. Long-term hyperglycemia in blood 
could affect various organs in our body such as eyes, kidney, heart, and brain. The 
figure adapted from IDF atlas 7
th




1.9  Current methods or biomarkers to detect ED 
The function of an endothelium can be assessed by the ability of an artery to 
dilate in response to physical or chemical stimuli, or by measuring biomarkers of 
endothelial activation, dysfunction, and damage. There are several invasive and 
non-invasive methods of EC function assessment. The functional assessment of 
EC responses can be measured by assessing vasodilation in response to the 
intravenous infusion of acetylcholine which is the standard method for the 
identification of endothelial dysfunction in the various vascular diseases such as 
hypertension, diabetes, hypercholesterolemia, congestive heart failure or 
atherosclerosis [59]. However, the invasive approach of this technique limits their 
repeated use for large-scale studies of endothelial dysfunction and it was soon 
replaced by the development of non-invasive approaches such as branchial artery 
flow-mediated vasodilatation (FMD), gauge-strain plethysmography, peripheral 
arterial tonometry, Pulse Wave Analysis, Laser Dopper flowmetry combined with 
iontophoresis of vasoactive agents such as acetylcholine, bradykinin, or serotonin 
[60-62]. These techniques measure the arteries ability to respond by endothelial 
NO release during post-occlusive reactive hyperemia and it independently 
predicts the cardiovascular events comparing healthy individuals and populations 
with risk [63]. Apart from these, the integrity of endothelium can be assessed by 
measuring compounds released by ECs using enzyme-linked immunosorbent 
assay (ELISA). E-selectin and P-selectin are important mediators of inflammation 
and their presence as soluble forms in the plasma indicates EC activation or 
damage in cardiovascular disease and diabetes [64]. Von Willebrand factor 
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(VWF) has an essential role in the regulation of vascular homeostasis by 
promoting platelet aggregation and adhesion upon injury. The increase in plasma 
VWF level inversely correlates with endothelial function, which could be a 
potential predictor of ischemic stroke and coronary heart disease [65, 66]. But 
none of these biomarkers have been found to associate with endothelial 
dysfunction or reported as diagnostic markers to identify a vascular disease in 
early stage. Therefore, there is a need to identify potential biomarkers that could 
indicate endothelial dysfunction during early stages of disease progression. 
Endothelial health is a key factor for numerous cellular events, including 
regulation of selective molecular transport, vascular tone, angiogenesis, 
inflammation, platelet aggregation, and thrombosis. The impairment of 
endothelial function is a systemic process, which contributes in many vascular 
diseases. Endothelial function can be assessed by ultrasound flow-mediated 
vasodilation (FMD), peripheral arterial applanation tonometry, digital pulse 
amplitude tonometry, Gauge-strain plethysmography and catheter-based methods. 
None of these current methods of measuring endothelial dysfunction fulfill all the 
clinical requirements. Hence, there is a need for an appropriate biomarker to 
precisely evaluate the pathological status. An ideal endothelial function test 
should be least invasive, affordable, and reproducible. Recently, dysregulation of 
miRNA expression has reported to be implicated in various pathological 
conditions and they are reported to be present in plasma, rendering them as useful 
stable biomarkers to be detectable in the early stages of the disease. The use of 
miRNAs as potential biomarkers and therapeutic targets are now recognized 
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worldwide.  Many of these miRNAs have already been validated in clinically 
relevant animal models and a few are also in preclinical trials to demonstrate their 
promising role in the development future therapies. Nevertheless, only a few 
miRNAs have been identified so far to be specific for endothelial dysfunction and 
related diseases. 
1.10  miRNAs- biogenesis and function 
MicroRNAs (miRNAs) are small (20 – 24 nucleotides), endogenously expressed, 
single-stranded, non-coding RNA molecules. They play a pivotal role in the 
regulation of gene expression, to control a wide range of biological functions such 
as cellular metabolism, proliferation, differentiation and apoptosis [67]. Currently 
with the help of various experimental techniques such as high – throughput next 
generation RNA sequencing and robust computational approaches like miRBase, 
ab-inito method, a total of 30,424 mature miRNAs have been identified in 206 
species (miRBase database, version 21.0, June 2014) [68-71]. Computational 
prediction shows that miRNAs constitute nearly 1% of all the predicted protein 
coding genes in C.elegans, Drosophila, and mammals [72-74]. In the human 
genome, 2578 miRNAs that have been identified controls more than 30 – 60 % of 
the protein-encoding genes [68]. The initiation of miRNA biogenesis starts with 
the transcription of miRNA genes into primary miRNA transcripts (pri-miRNAs) 
[75] with the help of either RNA polymerase II [76] or RNA polymerase III [77]. 
The pri-miRNAs are generally several kilobases long, capped at 5’ UTR, 
followed by polyA tail in the 3’ UTR [78]. The pri-miRNAs fold into a hairpin 
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structure, which acts as a substrate for endonucleolytic cleavage by the 
microprocessor complex namely Drosha [78] and Di-George Critical Region 8 
(DGCR8/Pasha) RNase III enzymes [79]. In this process, Drosha cleaves the 5’ 
and 3’ arms of the stem loop hairpins in pri-miRNAs whereas DGCR8 interacts 
stably with the pri-miRNAs and acts as a molecular ruler to locate the precise 
cleavage site [80]. The product of microprocessor complex, is approximately 
about 70 nucleotide base pair, referred to as pre-miRNAs is now ready to be 
exported into the cytoplasm with the help of the Exportin – 5 (XPO5) in complex 
with RAs-related Nuclear protein- Guanosine triphosphate (Ran-GTP) [81]. In the 
cytoplasm, the another RNase III family of enzymes namely Dicer cleaves the 
loop of the pre-miRNAs into an 18 -22 nucleotide base pair miRNA duplexes 
with two nucleotides overhanging at the 3’ ends [82]. One of these strands is 
incorporated into RISC (RNA- Induced Silencing Complex) and guides the 
complex to target its specific mRNAs for the translational inhibition or 
degradation (Figure 1.7) [83]. The interest on miRNAs has now been increased 
with a seminal work of Mitchell et al, [84] that showed the presence of circulatory 
miRNAs in the human plasma. These miRNAs in plasma are resistant to 
degradation by endogenously produced RNAses and it was also found to be 
remarkably stable under various harsh conditions such as multiple freeze- thaw 
cycles, boiling, low or high pH [85-87]. These led to the idea that the circulatory 
miRNAs could act as intercellular signaling molecules as well as potential 




Figure 1.7:  Biogenesis and secretion of miRNAs into circulation. miRNAs have 
diverse functions in our body. It is biosynthesized within the cells for action as 
regulators of cell signaling and also for having hormone-like properties as the 
circulatory miRNAs. The figure adapted from Schwarzenbach et al, 2014 [87].  
1.11  miRNAs in vascular pathology and ED in T2DM 
Exposure of ECs to hyperglycemia in the blood will alter its quiescence 
state and impair normal function. Endothelial dysfunction is characterized by 
enhanced endothelial permeability, an imbalance in vasoactive agent’s synthesis, 
elevated leukocyte adhesion molecule expression and reduced antithrombotic 
properties [39, 40]. In early phases of EC activation (type1), an increase in the 
intracellular calcium levels initiates vascular EC hyperpermeability, exocytosis of 
WPBs to release VWF and brings p-selectin to the luminal side of the EC thereby 
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promoting leukocyte infiltration [38].  In the later stages of EC activation (type 2), 
proinflammatory molecules such as TNF-α and NF-kB induce the expression of 
proinflammatory genes such as VCAM1, ICAM1, and E-selectin which causes an 
increase in the permeability of molecules, tight junction disruption, migration, 
thrombosis and EC death [39]. Recently, research on endothelial cell function has 
gained much attention in the field of vascular biology, particularly their 
implications in vascular dysfunction and diseases such as diabetes, stroke, 
cardiovascular disease, hypertension, erectile dysfunction and peripheral artery 
disease [57-63].    
Poy et al, [88] was the pioneer who studied about the role of miRNAs in diabetes 
and they identified miR-375 as a novel regulator of insulin secretion. From then 
onwards, there has been an exponential increase in the study of molecular 
mechanism of miRNA-based regulation of gene expression in diabetes.  
Hyperglycemia is a major risk factor during diabetes that is involved in the 
development of endothelial dysfunction, but the underlying mechanism seems to 
be multifactorial in nature [89]. The impairment of glucose metabolism leading to 
hyperglycemia is a hallmark of type II diabetes, which activates various metabolic 
pathways such as polyol pathway, hexosamine biosynthesis pathway (HBP), 
advanced glycation end products (AGE) and oxidative stress pathway [90]. 
During diabetes, 30% of excess glucose is diverted through the aldo-reductase 
(AR) dependent polyol pathway [91]. The rate limiting step in the polyol pathway 
is the reduction of glucose to Sorbitol by a key enzyme aldo-reductase (AR) [91]. 
The increase in polypol pathway could deplete the Nicotinamide adenine 
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dinucleotide phosphate (NADPH) and Glutathione (GSH) level to result in an 
imbalance in Reactive Oxygen Species (ROS) production. In the second step of 
polyol pathway, sorbitol is converted into fructose by sorbitol dehydrogenase 
(SDH) during which NAD
+
 is converted into Nicotinamide adenine dinucleotide 
hydrogen (NADH). NADH will act as a substrate for NADH oxidase for the 
production of superoxide anions. The high glucose-induced AR upregulates ROS 
production [92] whereas, inhibition of AR prevents diabetics induced blood-
retinal barrier breakdown, but the overexpression of human AR causes an increase 
in infarct volume and ischemia-reperfusion injury in the heart [92]. AR inhibition 
has been shown to downregulate miR-21 and thus, the pathology during 
hyperglycemia could be attributed to an AR induced increase in miRNA-21 
expression which causes cell death via down-regulation of its targets PTEN and 
FOXO3a [93, 94]. Oxidative injury due to hyperglycemia is known to activate 
multiple signaling pathways which in turn lead to increase in expression of 
several key molecules such as MAPK, ELK, and PKC isoforms to induce vascular 
damage. Feng et al, [95] showed that exposure of high glucose to HUVEC 
induces the expression of vasoactive compounds and extra cellular matrix (ECM) 
proteins and it is mainly due to downregulation of miR-320. During diabetes there 
is an increase in the production of advanced end glycation products and DAG 
formation, thereby PKC isoforms are activated to promote the vascular 
complications. The inhibition of aldose reductase could prevent the translocation 
and phosphorylation of PKC isoforms by inhibiting DAG formation [96]. PKC 
exists in several isoforms such as classical, novel and atypical. PKC-α promotes 
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arginosuccinate synthase phosphorylation at serine 328 and activates eNOS 
phosphorylation at serine 1177 to increase the NO production in ECs. But 
interestingly, the ROS production inside the EC due to hyperglycemia could 
inactive NO and causes endothelial dysfunction. Recently Karolina et al, in 2011 
reported that miRNA-144 involves in the insulin signaling by directly targets the 
IRS-1 both in vitro and in vivo [97]. There are several other miRNAs involved in 
the Diabetes  that are also well documented by the review by Karolina et al, in 
2012 and others [98-101]. 
The importance of miRNAs in EC function and blood vessel development 
was discovered by disrupting the function of Dicer and Drosha that are required 
for miRNA biogenesis. The depletion of Dicer using siRNAs in ECs altered 
several key regulators of EC biology and angiogenesis including growth factor 
receptors, chemokines, cytokines and several other angiogenesis-related genes, 
such as Tie-1, Tie-2, Id3, eNOS, IL-8, ENG (Endoglin), AKT1 and VEGFR2. 
Genetic silencing of both Dicer and Drosha significantly reduced capillary 
sprouting and proliferation of ECs. Loss of the first two exons of the Dicer gene 
(Dicerex1/2) in mice led to lethality in early embryogenesis due to defective 
blood vessel formation and maintenance. In the in vivo matrigel plug assay, 
vessel-like structures were significantly reduced in matrigel plugs with Dicer 
knockdown in HUVECs. To address the importance of endothelial-specific 
miRNAs in postnatal angiogenesis, Suárez Y et al, [102] generated two mouse 
models that were homozygous for the conditional floxed Dicer allele and 
expressed cre-recombinase under the regulation of Tie2 promoter or tamoxifen 
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(TMX)-inducible expressed cre-recombinase under the regulation of vascular 
endothelial cadherin promoter to achieve specific inactivation of Dicer in ECs. 
Through these models, it was shown that reduction of endothelial miRNAs by 
cell-specific inactivation of Dicer reduced postnatal angiogenic responses to a 
variety of stimuli, including exogenous VEGF, tumors, limb ischemia, and wound 
healing. Recent data implicated certain miRNAs as crucial determinants of EC 
behavior during angiogenesis [103]. EC-restricted miRNA miR-126 is essential 
for normal angiogenesis in mice and zebrafish [104]. miR-126 is located in intron 
7 of the endothelial gene epidermal growth factor-like 7 (EGFL7) [105].  
Expression of miR-126 positively influences VEGF-induced signaling by post-
transcriptionally repressing SPRED1 (Sprouty-related EVH1 domain containing 
1) and PI3K regulatory subunit 2 (PIK3R2; also known as p85β), which are 
negative regulators of MAPK and PI3K signaling, respectively.  Consequently, 
enhanced SPRED1 and PIK3R2 expression upon miR-126 knockdown blocked 
VEGF-induced MAPK and PI3K signaling. As a result, angiogenesis and vascular 
integrity were compromised in mice or zebrafish deficient for miR-126, resulting 
in fragile and leaky vessels that caused hemorrhage [106]. 
Senescence is connected with a cellular response to various environmental 
stressors and damages defined as permanent cell cycle arrest [107]. Senescent 
cells are important in atherothrombosis and are related to various age-related 
diseases, including atherosclerosis, and cardiovascular disorders. Several miRNAs 
has been reported to be involved in the mechanism of EC senescence. Recently, 
OncomiR-21 has been reported to contribute to the endothelial senescence 
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induced cell growth arrest [108] by targeting NFIB (nuclear factor 1 β-type) and 
CDC25A (cell division cycle 25A) [108]. Yet another study by Zhu et al, [109] 
showed the role of miR-21 in endothelial progenitor cell senescence via 
suppressing high-mobility group A2. Van Balkom et al, [110] showed that miR-
214 alters ATM gene expression during EC senescence. miR‑34a is already 
expressed in primary ECs and the degree of expression increases during cell 
senescence. Overexpression of miR‑34a in ECs decreases SIRT1 and increases 
acetylation of p53. Additionally, acetylated tumor suppressor p53 promotes 
miR‑34a expression, which accelerates suppression of SIRT1 and ultimately 
results in cell senescence [111]. Overexpression of miR‑34a in the endothelial 
progenitor cells (EPCs) also reduces SIRT1 and remarkably increases cell 
senescence. Similarly, silencing SIRT1 by siRNA resulted in reduced 
EPC‑induced angiogenesis and increased cell senescence [112]. Another miRNA, 
miR‑217, is expressed in young HUVECs, human aortic ECs, and human 
coronary artery ECs. miR‑217 promotes endothelial senescence through  
inhibition of SIRT1, which affects functions of  the SIRT1/forkhead box protein 
O1 (FOXO1)  pathway.   miR‑217 was absent in young cells but increased during 
endothelial senescence [113]. A recent study has demonstrated that miR‑200c 
influenced growth arrest, apoptosis, and senescence of HUVECs in response to 
reactive oxygen species (ROS). miR‑200c targets zinc finger E‑box‑binding 
homeobox 1 (ZEB1). Downregulation of ZEB1 protein by ROS and increase in 
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expression of miR‑200c alters induction of the p53 and retinoblastoma protein 
tumor suppressor pathways responsible for cellular senescence [114]. 
1.2 Hypothesis of this study: 
There has been increasing reports on circulating miRNAs as potential biomarkers 
for the diagnosis of disease and identifying risk factors in patients susceptible to 
complications. Therefore, it is beneficial to study dysregulated miRNAs in the 
disease progression of diabetes. The hypothesis of this study is to identify the 
miRNAs that could differentiate the impaired fasting blood glucose (IFG) and 
type 2 diabetes (T2DM) patients from the healthy individuals. By studying these 
miRNAs and the process that they regulate, the mechanisms underlying the 
hyperglycemia induced vascular complications can be explored. These circulating 
miRNAs could also serve as potential biomarkers and/or therapeutic targets for 
diabetic related vascular dysfunction.  
1.3 Objectives: 
1. Identify dysregulated miRNAs that differentiate the IFG and T2DM from 
healthy individuals. 
2. Identification of biological pathways dysregulated during IFG and T2DM. 
3. Establishment of an in vitro model of hyperglycemia induced endothelial 
dysfunction. 















Materials and methods 
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2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Cell line and cell culture reagents 
Human Umbilical Vein Endothelial Cells (HUVECs, CRL-1730
TM
) were acquired 
from the American Type Cell Culture (ATCC, Manassas, VA, USA). 
2.1.1.1 Saline 
NaCl (0.9%, w/v) was weighed using a clean weighing paper and dissolved in 
sterile deionized water and autoclaved for 20-30 mins to make it sterile. Once 
cooled, it was stored at room temperature. 
2.1.1.2 1X Phosphate saline buffer (PBS)   
NaCl      137 mM  
KCl      2.7 mM 
Na2HPO4.7H2O    10 mM 
KH2PO4     1.8 mM 
The chemicals were dissolved in 1 litre of sterile deionized water and the pH was 





2.1.1.3 1X Trypsin 
10X trypsin stock (Thermo Fisher Scientific, MA USA) was diluted with saline to 
prepare 1X trypsin and filtered using 0.2 µm filter and sterile syringe. The 
solution was stored at 4°C. 
2.1.1.4 Glycerol stock  
100% glycerol was autoclaved and used to stock cells at different passages. 
2.1.1.5 Basal Dulbecco's Modified Eagle's Medium (DMEM; 1 L)  
DMEM powder    17.4 g 
L-glutamine     0.4 g 
Sodium bicarbonate    1.74 g 
Penicillin-Streptomycin (50 U-50 mg/ml)  1% 
The above mentioned chemicals were dissolved in 1 liter of sterile deionized 
water. The pH was adjusted to 7.3 using 5 M sodium hydroxide and the medium 
was filtered using sterile 0.22 µm filter.  
2.1.1.6 Complete medium (1 L) 
Basal DMEM     890 ml 
Fetal Bovine Serum (FBS)   100 ml 
Penicillin-Streptomycin   10 ml 
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2.1.1.7 Freezing medium (10 ml) 
Basal DMEM     3 ml 
FBS      7 ml 
The preparation was carried out aseptically and the medium was stored at 4°C. 
Prior to usage, the medium was warmed in a 37°C water bath. This freezing 
medium together with 10% sterile autoclaved glycerol was used to stock 
HUVECs at -80°C.  
2.1.1.8 Glucose DMEM (1 M) 
1.8g of D
+
-Glucose was weighed on a clean weighing paper and dissolved in 
10ml of DMEM without glucose and it was filtered using 0.22 µm sterile filter. 
 2.1.1.9 DMEM with various concentration of glucose 
Glucose-free basal DMEM (Invitrogen, Carlsbad, CA, USA) was added with 
different volumes of 1 M glucose to prepare DMEM with different concentrations 
of glucose as below:  
Glucose Final concentration 
in DMEM 
1 M glucose stock 0 mM glucose DMEM 
1 mM 50 µl 50.00 ml 
5 mM 250 µl 49.75 ml 
10 mM 500 µl 49.50 ml 
25 mM 1250 µl 48.75 ml 
40 mM 2000 µl 48.00 ml 
Table 2.1 Preparation of glucose stock  
36 
 
2.1.2  Reagents for cell based assay 
2.1.2.1 Cell viability assay 
2.1.2.1.1 MTT solution 
MTT       10 mg 
Autoclaved water    1 ml 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) powder 
was weighed and dissolved completely in sterile water by vortex well. The 
solution was stored at 4°C after wrapping in aluminum foil. Working 
concentration was kept as 0.5 mg/ml. 
2.1.2.2 Cytotoxicity 
2.1.2.2.1 Lactate dehydrogenase assay 
The cytoplasmic enzyme lactate dehydrogenase (LDH) released into the cell 
culture was used as a standard marker to measure cytotoxicity. To measure the 
LDH level, cytotoxicity detection kit from Sigma-Aldrich, Roche Diagnostics 
(MO, USA) was used. 
2.1.2.3 Glucose uptake measurement kit 
The glucose uptake into the cell and the glucose remaining in the cell culture 
medium were measured using glucose (HK) assay kit (GAHK-20) (Sigma, Saint 
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Louis, Missouri, USA). The assay was preformed according to manufacturer’s 
recommended protocol. 
2.1.2.4 Vascular endothelial growth factor A (VEGFA) quantification kit 
VEGFA is an endothelial growth factor, highly released into the cell culture 
medium upon apoptosis. It is measured by an ELISA kit following manufacturer’s 
protocol (Invitrogen, CA, USA) according to manufacturer’s protocol.   
2.1.2.5 Evan’s blue dye (10X) 
Stock solution (0.1%):   
Evan’s blue powder      100 mg 
Autoclaved water     10 ml 
Evan’s blue dye was prepared by dissolving the dye powder in autoclaved sterile 
water. It was stored in a dark place at 4°C. 
Working solution (0.01%):  
Evan’s blue stock solution     1 ml 
Autoclaved water     10 ml 





2.1.2.6 Methanol (50%) 
50% Methanol was prepared by diluting the 100% methanol using sterile distilled 
water in the ratio of 1:1. 
2.1.2.7 Solublization dye:  
Sodium dodecyl sulfate    1 mg 
50% methanol     100 ml 
2.1.3 Reagents for Immunocytochemistry (ICC) 
2.1.3.1 Formaldehyde (4%) 
Formaldehyde (37 %, v/v) (Merck, USA) was freshly diluted in 1X PBS (section 






(0.1%) was freshly prepared by diluting in 1X PBS (section 
2.1.1.2).  
2.1.3.3 Blocking reagent 






2.1.3.4 3-dye staining kit 
The 3-dye (FITC-Annexin V, ethidium homodimer III and Hoescht 33342) 
staining kit (Biotium, CA, USA) was used to quantify healthy, apoptotic, and 
necrotic cells. The assay was performed according to the manufacturer’s protocol. 
2.1.3.5 Mounting medium 
Aqueous faramount mounting medium (Dako, USA) was used to mount the 
coverslips fixed with cells onto microscopic slides.  
2.1.4 Reagents for RNA extraction from HUVECs 
2.1.4.1 Chloroform 
100% chloroform was saturated with sterile distilled water and mixed well and 
allowed to settle at room temperature. 
2.1.4.2 Ethanol 
Ethanol (75%, v/v) was prepared by diluting 3 parts of 100% ethanol with 1 part 
of sterile deionized water. 
2.1.4.3 Diethylpyrocarbonate (DEPC)-treated water 
DEPC       0.2 ml 
Deionized water     100 ml 
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DEPC was carefully added to the deionized water and mixed thoroughly in a 
fume hood. The DEPC in the solution was inactivated by autoclaving the solution 
and stored at room temperature. 
2.1.5 Reagents for RNA agarose gel electrophoresis 
2.1.5.1 Morpholinopropanesulfonic acid (MOPS) running buffer (10X) 
 MOPS (pH 7.0)    0.4 M 
 Sodium acetate    0.1 M 
 EDTA (pH 8.0)    10 mM 
The above were dissolved in DEPC treated water and filtered using 0.22 µm 
sterile filter. Using DEPC treated water 1X MOPS was prepared as working 
solution for running agarose gel electrophoresis.  
2.1.5.2 Deionized formamide 
Five hundred ml of Formamide was stirred with 500 mg of Dowex XG8 resin for 
1 hr and filtered through Whatman No.1 filter paper. Deionized formamide was 
stored at room temperature covered in aluminum foil at room temperature.  
2.1.5.3 Ethidium bromide (10mg/ml) 
Ethidium bromide      10 mg 
Autoclaved water     1 ml 
The solution was with aluminum foil and stored at dark place. 
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2.1.5.4 RNA sample master mix 
Deionized formamide    10 µl 
37% Formaldehyde    3.5 µl 
10X MOPS     2 µl 
2.1.5.5 RNA loading buffer 
 Glycerol     50% (v/v) 
 Bromophenol blue    0.4% (w/v) 
 EDTA (pH 8.0)    1 mM 
2.1.5.6 RNA agarose gel (1%) 
 Molecular grade agarose    0.5 g 
Deionized water    4.3.5 ml 
37% Formaldehyde    1.5 ml 
10X MOPS     5 ml 
Ethidium bromide    1 µl 
Agarose in powdered form was weighed accurately and mixed with water and 
heated to 100°C, to melt completely. It was then cooled to about 60°C before 




2.1.6  Reagents for RNA polyacrylamide gel electrophoresis   
2.1.6.1 Ammonium persulphate (APS) 10% w/v 
 Ammonium persulphate   100 mg 
 Autoclaved deionized water   10 ml 
APS powder was dissolved completely in water without foaming and stored at -
20°C. 
2.1.6.2 10X Tris-Borate-EDTA (TBE) buffer (1 L) 
Tris base (w/v)    890 mM 
Boric acid     890 mM 
0.5M EDTA (pH8.0) (v/v)   20 mM 
Deionized water    960 ml 
Tris base and boric acid were dissolved in 800 ml of deionized water along with 
40 ml of EDTA, pH8.0 to a final volume of 1 litre.  
 2.1.6.3 Denaturing polyacrylamide gel (15%) 
   Urea      7.2 g 
   40% Acrylamide    5.63 ml 
   10X TBE buffer    1.5 ml 
  Deionized water    0.95 ml 
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  TEMED     7.5 µl 
  10% Ammonium persulphate (APS) 37 µl 
Urea was mixed with acrylamide and 10X TBE buffer and heated to 60°C until 
dissolved completely. Then deionized water, TEMED and APS were added to the 
mixture and the mixture was used immediately to cast the gel. 
2.1.6.4 RNA sample buffer (Per sample)  
 10X TBE buffer      2 µl 
 Deionized formamide  (Section 2.1.2.4)   10 µl 
 RNA loading buffer (Section 2.1.3.3)   3 µl 
Ethidium bromide (10 mg/ml)    1 µl 
2.1.7  Reagents for miRNA array 
2.1.7.1 miRNA dephosphorylation (per sample) 
 Spike-in miRNA       2.0 µl  
 Calf intestinal alkaline phosphatase (CIP) Buffer   0.5 μl 
CIP Enzyme        0.5 μl 
2.1.7.2 miRNA labeling (per sample) 
Labeling buffer       3.0 μl 
Hy3 Fluorescent label      1.5 μl 
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DMSO        2.0 μl 
Labeling Enzyme       2.0 μl 
2.1.7.3 Wash buffers 
2.1.7.3.1 Wash buffer A 
    20X Salt buffer       60 ml 
    10 % Detergent solution      12 ml 
    Sterile water       528 ml 
Wash buffer A and two washing dishes were pre-warmed overnight to 56 °C prior 
to use. 
2.1.7.3.2 Wash buffer B 
    20X Salt buffer       20 ml 
    Sterile water       380 ml 
2.1.7.3.3 Wash buffer C 
    20X Salt buffer      2 ml 





2.1.8  Reagents for quantitative polymerase chain reaction (qPCR) 
2.1.8.1 Reverse transcription (RT) mixture for mRNA 
Reverse transcription buffer (10X)    1.0 µl 
MgCl2 (25 mM)      2.2 µl 
dNTPs Mixture (2.5 mM)     2.0 µl 
Random hexamers (50 µM)     0.5 µl 
RNase inhibitor (20 U/µl)     0.2 µl 
MultiScribe
TM
 reverse transcriptase (50 U/µl)  0.25 µl 
RNase free water      1.85µl 
The reagents were obtained from SYBR green reverse transcription kit (Catalog 
No: 4309155) (Applied Biosystem, Caelsbad, CA, USA).  
2.1.9  Stem–loop real time PCR  
2.1.9.1 Reverse transcription master mixture for Taqman
®
 miRNA assay 
10X RT buffer     1.5 µl 
DeoxyNTPs mixture (100 mM)   0.15 μl 
RNase inhibitor (20 U/μl)    0.19 μl 
MultiScribe TM Reverse Transcriptase (50 U/μl) 1.0 μl 
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Autoclaved Water      4.16 μl 
Stem-loop primer      3 μl  
RNA (5 ng/μl)      2 μl 
2.1.10 SYBR green assay for mRNA 
 2 X SYBR Green PCR Master Mixture   10 μl 
Forward primer (10 μM)     0.6 μl 
Reverse primer (10 μM)     0.6 μl 
Nuclease-free water      3.8 μl 
The SYBR green real-time PCR master mixture and primer-probes were obtained 
from Applied Biosystems (USA). Gene specific forward and reverse primers for 
SYBR Green assays were purchased from 1st Base (Singapore). 
2.1.11 Taqman assay for miRNA 
2 X Taqman Universal PCR Master Mixture   10.0 μl 
(Without AmpErase® UNG) 
20 X Taqman miRNA probe      1.0 μl 
Nuclease-free water       7.67 μl 
The TaqMan Universal PCR Master Mixture reagent, customized primers, and 




2.1.12  β-galactosidase assay 
The senescence in endothelial cell was measured using β-galactosidase staining 
kit (Cell Signaling, USA - Catalog No: 9860). The quantification of β-
galactosidase stain was performed according to manufacturer’s protocol 
2.2  Methods 
2.2.1  Cell culture 
Human Umbilical vein endothelial cells (HUVECs) were purchased from ATCC 
(CRL-1730) and grown in a T75 flask using 5mM glucose Dulbecco’s Modified 
Eagle Medium (DMEM; Thermo Fisher Scientific, MA USA) supplemented with 
2mM L-glutamine, 10% fetal bovine serum (FBS) and 1% penicillin (100 IU/ml) 
and streptomycin (100 µg/ml) (Thermo Fisher Scientific, MA USA) in the 
presence of 5% CO2 at 37
ο
C. Media were changed every 48 hours until the cells 
reached 80-90% confluence. The cells (between passages 3 to 6) were then sub-
cultured in serum starved 5mM glucose DMEM containing 1% FBS. After which, 
they were seeded at a density of 6 x10
4
 cells/well in 24 well plates (Greiner bio-
one, Cell star, Austria) and grown for another 24 hours to reach 80-90% 
confluence before treating them separately with media containing different 






2.2.2  Cell viability assay 
The cell viability was determined by 3-[4, 5-dimethylthiazol-2-yl]-2, 5-
diphenyltetrazolium bromide (MTT; Sigma, MO, USA). This is a colorimetric 
assay, which measures the reduction of MTT into an insoluble formazan crystal 
product by the conversion of active mitochondrial enzymes in viable cells. 
HUVECs were seeded at a density of 6 x 10
4
 cells in 24 well plates and treated 
with different concentrations of glucose for 6, 12, 24 and 48 hrs.  10 µl of MTT 
(10 mg/ml) was added one hour before the end point. The media were aspirated 
separately and the cells were lysed by adding 200 µl of Dimethyl Sulfoxide 
(DMSO; Sigma, MO, USA) to each well. The crystals were completely dissolved 
by gently shaked in the shaker. 100 µl of the dissolved crystal solution was 
transferred to 96-well plate. The optical density of each sample was measured in a 
microplate reader (Model 680; Biorad, CA, USA) at 570 nm. 100 µl of DMSO 
was used as a reagent blank. The cell viability was represented as percentage by 
statistically comparing the OD value of treated and untreated cell samples. t-test 
was used for significance at 95% 
2.2.3 Cytotoxicity assay 
The cytotoxicity detection kit was fast, reliable and simple colorimetric assay to 
measure cell death. During apoptosis, the cell loses its membrane integrity and 
releases the cytoplasmic lactate dehydrogenase (LDH) into cell culture medium. 
HUVECs incubated with Triton X-100, (Sigma-Aldrich, MO, USA) for 30 mins 
at 37°C was used as positive control. At the end of a treatment time intervals, the 
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culture medium was collected and centrifuged for  10 mins  at  14000 rpm,  in  
order  to  remove  any  cellular  debris. 100 μl of the supernatant was transferred 
to a 96-well plate. 50 µl from each culture medium was withdrawn and mixed 
with 50 µl of cytotoxicity detection assay kit reagent (Sigma-Aldrich, Roche 
Diagnostics, MO, USA) kept in a microtiter plate at room temperature for 30 
mins. The samples were mixed well and the absorption was measured at 490 nm 
in a microplate reader (Model 680; Biorad, CA, USA).The cytotoxicity was 
measured as a percentage of the total cellular LDH activity. 
2.2.4  Total RNA (including miRNAs) isolation 
Upon completion of treatment at different time intervals (6/12/24/48 hrs), medium 
from 24-well plates were collected in separate Eppendorf tubes and stored in -
80°C.  The cells were washed with 1X PBS (section 2.1.1.2) two times. 1ml of 
TRIzol
®
 reagent was added per 3 wells of a 24 well plate treatment and the cells 
were lysed by pipetting up and down using blue tips to completely break the cell 
membrane. The cells in TRIzol
®
 were now collected into a 1.5 ml eppendorf tube 
and either stored in -80°C for later use or processed for RNA extraction 
immediately according to manufacturer’s protocol. Briefly, 200 µl of water 
saturated chloroform was added to each sample in eppendorf tubes and mixed 
vigorously. The samples were kept in ice for 2-3 mins before they were 
centrifuged at 14,500 rpm for 15 minutes at 4°C.The aqueous phase was carefully 
collected into a new eppendorf tube and 3µl of DNase I was added to it. The 
samples were then incubated in a water bath at 37°C for 20 minutes. After that, 
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500 µl of isopropanol was added to the DNA digested RNA aqueous phase and 
mixed gently and left overnight at -80°C. Next day the total RNA was pelleted by 
centrifuging at 14,500 rpm for 15 minutes at 4°C. The pellet was washed by 
centrifuging with 1ml of ice cold 75% ethanol (section 2.1.4.2) at 10,500 rpm for 
5 minutes at 4°C. The supernatant was discarded and pellet was air dried at room 
temperature. Finally, the pellet was solubilized in 20 µl of sterile nuclease-free 
water at 60°C for 10 minutes. RNA concentration and purity was determined by 
Nanodrop
TM
 N2000c spectrophotometer (Thermo Scientific
TM
, Rockford, IL, 
USA) and RNA gel electrophoresis respectively. The small RNAs presence was 
confirmed by 15% polyacrylamide gel electrophoresis. 
2.2.5  RNA gel electrophoresis 
2.2.5.1 Agarose gel electrophoresis (1%) 
The integrity of the isolated RNA was checked using denaturing formaldehyde 
agarose gel electrophoresis. The molten agarose (Selection 2.1.5.6) was poured 
into a tape sealed horizontal gel-casting tray and an appropriate “comb” was 
inserted to form wells for loading RNA samples. Once the gel had solidified, the 
“comb” was detached and the gel was placed into the electrophoresis tank 
containing 1X MOPS as running buffer. RNA samples (approximately 600ng) 
were mixed with the sample buffer (Section 2.1.5.5) and incubated at 65
o
C in the 
water bath for 10mins and loaded into the gel wells. Electrophoresis was carried 
out at 80V for approximately 30 mins and the migration of bands was viewed 
using a UV illuminator (Cell biosciences, Santa clara, CA, USA). 
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2.2.5.2 Denaturing polyacrylamide gel electrophoresis (PAGE) (15%) 
The integrity of the small RNAs (includes miRNAs) was analyzed using 
denaturing polyacrylamide gel electrophoresis. The polyacrylamide gel was 
prepared as described in section 2.1.6.3 and the molten PAGE gel was casted in a 
vertical gel-casting tray. A comb was used to create wells for sample loading. 
After solidification, the comb was removed and the gel submerged into an 
electrophoresis tank containing 1 X TBE running buffer (section 2.1.6.2). The gel 
was pre-run for 30 minutes at 100 V while the RNA samples were mixed with the 
sample buffer (section 2.1.6.4) and heated at 95°C for 5 minutes. The samples 
were chilled immediately in ice and spun down before loading into the gel wells. 
Electrophoresis was carried out at 100 V for about 2 hours and the gel was stained 
in water containing 1 μl of 10 mg/ml ethidium bromide (section 2.1.5.3). The 
migration of the bands was viewed using a UV illuminator (Cell Biosciences, 
Santa Clara, CA, USA). 
2.2.6  LNA-based miRCURY LNA
TM
 arrays 
LNA-modified oligonucleotide probes (Exiqon, Denmark; Catalogue number - 
208410) for human, mouse and rat miRNAs annotated based on miRbase version 








 miRNA sample labeling 
All the components required for labeling were thawed on ice. 500 ng of total 
RNA (Including miRNAs) were used to perform each array which contains more 
than 1769 capture probes that could recognize it’s complementary sequences from 
different species such a human, mouse, rat, related viral sequences and spiking 
control. Total RNA was labeled at 3’end using Hy3 dye and miRCURY LNATM 
miRNA power labeling kit (Exion, Vedbaek, Denmark). 
Two μl of the CIP mixture (section 2.1.12.1) was mixed with the RNA sample in 
a PCR tube and incubated in a PCR machine at 37°C for 30 minutes followed by 
95°C for 5 minutes. The reaction was snap cooled in ice to terminate the reaction. 
The sample was spun down and 8.5 μl of the labeling mixture (section 2.1.12.2) 
was added. The miRNAs were labeled with Hy3 fluorophores in a PCR cycler 
with heated lid at 16°C for 1 hour followed by 65 °C for 15 minutes. The samples 
were protected from light and kept at 4°C for hybridization which was performed 
within 2 hours of labeling. 
2.2.6.2 Sample preparation for hybridization 
The labeled product was diluted in 12.5 μl of nuclease-free water and the contents 
transferred into a new PCR tube. Twenty five μl of 2 X hybridization buffer 
(Exiqon, USA) was added to the sample and the contents vortexed and spun 
down. The sample was denatured at 95°C for 2 minutes and cooled on ice. Before 
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loading the sample, pipette tips were pre-wet in 50 μl of 1 X hybridization buffer 
in nuclease-free water pre-warmed at 56°C. 
2.2.6.3 Setting up of hybridization chamber 
The MAUI hybridization chamber was switched on and pre-heated to 56°C. The 
miRCURY LNA™ microRNA Array chip (miRBase version 16.0) was warmed 
on the pre-heated block for 5 minutes and loaded onto a chip holder. A cover was 
aligned onto the exposed surface of the array chip to seal the exposed chip surface 
(Exiqon, Denmark). The enclosed chip assembly was placed back into the MAUI 
hybridization chamber for sample loading. 
2.2.6.4 Loading of sample for miRNA array 
Before sample loading onto the array slide, the pipette tips were pre-wet with 1 X 
hybridization buffer. Forty five μl of the sample was slowly injected into the chip 
via the inlet port in the chip cover to ensure no bubbles were introduced. Sample 
introduction was stopped when the fluid reached the outlet port of the cover. The 
excess fluid was wiped away and the ports sealed with an adhesive tape. The 
enclosed chip assembly was loaded onto the pre-heated MAUI® hybridization 
chamber, enclosed with a pre-wet humidity casing and closed. The slides were 
incubated at 56°C for approximately 16 hours. 
2.2.7  miRNA microarray data and statistical analysis  
LNA-modified oligonucleotide (Exiqon, Vedbaek, Denmark; Catalogue number - 
208410) probes for human miRNAs annotated in miRbase version 16.0 were used 
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in the microarray that was carried out in our laboratory. A total RNA of 1µg from 
three individual experiments (n=3) were pooled for each concentration of glucose 
treatment (0-40 mM glucose) and their respective time intervals (6-48 hrs). The 
3’end of RNA samples were labeled with Hy3 dye using miRCURY LNA power 
labeling kit (Exiqon, Vedbaek, Denmark; Catalogue number - 208410). The 
labeled RNA was hybridized on miRCURY LNA arrays, using MAUI 
hybridization system (BioMicro Systems, Salt lake city, UT) for 17 hours at 56
ο
C. 
The hybridized arrays were washed, fixed and scanned on InnoScan 700 
microarray scanner (Innopsys, Carbonne, France). The digitalized images were 
captured and analyzed by MAPIX
®
4.5 (Innopsys, Carbonne, France) microarray 
image analysis software.  Microarray analysis was carried out by background 
subtraction, t-Test/One-way ANOVA analysis, and hierarchical clustering. 
Normalization was performed using an average of multiple endogenous controls. 
A t-test was performed between 5mM glucose treated samples (Control) and 
“test” sample groups individually and the p-value was calculated for all the 
miRNAs. The hierarchical clustering method was used to detect the clustering 
pattern of samples across different concentrations of glucose treatment at various 
time intervals. The clustering was generated using TM4 MeV (Multiple 
Experimental Viewer) software and statistical evaluations were performed using 
Microsoft Excel (2010) data analysis such as two-tailed t-tests or in case of 
multiple comparisons using One-way ANOVA with significance level  p <0.05. 
Differential expression analysis of the miRNAs was performed using the FDR 
(Benjamini-Hochberg False Discovery Rate) correction (p < 0.05) as in Partek® 
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Genomics Suite™ 6.6 Software (Partek Inc, St Louis, MI USA). Hierarchical 
clustering (HCL) and k-means clustering were performed using TIGR MeV 
(TMeV) software and Partek® Genomics Suite™ 6.6 Software (Partek Inc., St. 
Louis, MI, USA) [275]. 
2.2.8  miRNA Pathway analysis  
DIANA (DNA Intelligent Analysis) miRpath [115] and miRWalk pathway 
analysis [116] were performed with the MicroT threshold cut-off value of 0.8 and 
p-value threshold <0.05. KEGG (Kyoto Encyclopedia of Genes and Genomes) 
pathway [117] was used for pathway analysis and top 20 pathways were selected. 
2.2.9  Assessment of nuclear morphology 
To characterize the pattern of cell death, nuclear morphology was observed by 
Hoechst 33342 staining and fluorescence microscopy. HUVECs seeded  and 
treated as for the microarray experiments were washed twice with 1X PBS and 
incubated with 0.1 µg/ml Hoechst 33342 (Biotium, CA, USA) for 15 mins in the 
dark and visualized under an Olympus IX51 microscope (Olympus, Japan) using  
DAPI (4',6-diamidino-2-phenylindole) fluorescence filter. Digital Images were 
captured with 20x objective using Olympus DP71 digital camera and Olympus 
DP controller software program. Cells with the morphology of fragmented or 
condensed pyknotic nuclei were considered as apoptotic and counted using image 




2.2.10  Flow cytometry  
The confluent monolayer of HUVECs treated with different concentrations of 
glucose for 24 and 48 hrs after washing twice with 1X PBS were gently detached 
using 0.05% of trypsin. The cells were collected in 2 ml eppendorf tubes and spun 
down at 800 rpm for 5 mins. The cell pellets were suspended in 500 µl of 1X 
annexin binding buffer and subjected to staining with 3 dyes: annexin V, 
Ethidium homodimer III, and DAPI, to detect apoptosis (Biotium, CA, USA) 
according to manufacturer’s protocol.  Flow cytometric analysis was performed 
by analyzing 10,000 events on a FACScan flow cytometer (BD biosciences, CA, 
USA) and the data were processed and analyzed using summit 4.0 software 
package. 
2.2.11  Caspase-3 assay 
 To determine whether the cells undergo caspase dependent apoptosis upon 
glucose treatment, both the active form of caspase-3 and caspase-3 activity were 
measured in the total cell lysate using Invitrogen human active caspase-3 ELISA 
kit (KHO1091; Life technologies, CA, USA) and (Alexis Corporation, Lausen, 
Switzerland) respectively according to manufacturers’ protocol. Background 
fluorescence was measured in wells containing lysis buffer, assay buffer and the 
substrate without cell lysate and used for the normalization of the test samples. 
For active caspase-3 measurement readings at 450 nm were obtained using 
microplate spectroflurometer (Spectra Gemini; Molecular devices, CA, USA). For 
caspase-3 activity, the fluorometric readings were measured at 405 nm absorption. 
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All the measurements were carried out in triplicates and for 3 independent sets of 
experiments.   
2.2.12  Polymerase chain reaction  
Total RNA was isolated from cultured cells using TRIzol (Invitrogen, Life 
Technologies Corporation, CA, USA). Reverse transcription followed by real-
time quantitative PCR (qRT-PCR) was carried out according to Jeyaseelan et al, 
[119]. Gene specific primers designed using PrimerExpress software (Version 
3.0) from Applied Biosystems (CA, USA) have been used for qRT-PCR on an  
Applied Biosystems 7900 sequence detection system (Applied Biosystems, CA, 
USA). The miRNA microarray results were validated with stem-loop real time 
qPCR. 10ng of total RNA was reverse transcribed and used for stem loop PCR. 
GAPDH was used as the endogenous control for both miRNA and mRNA 
measurements. Each reaction was performed in triplicates. 
2.2.13  Statistical analysis 
For both human and rat miRNA microarray data processing, Partek software 
(Missouri, USA) were utilized. The statistical analysis was performed using one-
way ANOVA followed by post hoc analysis with Bonferonni correction. For in 
vitro experiments, student t-test was performed. Pearson correlation was obtained 
from microarray data on HUVEC where modulus of Pearson correlation 
coefficient |R| > 0.8 indicated a strong correlation between the variables (miRNA 
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expression vs glucose concentration). Statistical significance was set at 95% 









miRNAs in impaired fasting blood 




3. miRNAs in impaired fasting blood glucose (IFG) and type 2 diabetes 
mellitus (T2DM) 
3.1  Introduction 
Diabetes Mellitus is a metabolic endocrine disorder characterized by the 
impaired metabolism of glucose and that result in high blood glucose level > 7 
mg/dl (hyperglycemia) [120], increase in hepatic glucose production [121], 
decrease in pancreatic insulin secretion [122] as well as increase in peripheral 
insulin resistance [123]. Diabetes has become one of the most common chronic 
diseases that create a major healthcare problem worldwide. The increases in 
sedentary life and lack of physical activities have made humans more prone to 
obesity and diabetes [124]. The World Health Organization (WHO) has estimated 
that there are currently 382 million people affected by diabetes worldwide and 
anticipates that if these trends continue by 2030 about 592 million people will 
have diabetes [125]. The international diabetic federation (IDF) reported that the 
global epidemic of type 2 diabetes for the year 2014 was 9% and it is expected to 
increase up to 9.9% in 2030. Among these 80% of the individuals are living in 
low-income countries. Nevertheless, it still remained as  the fourth or fifth leading 
cause of death in most high-income countries, with about 5.1 million death in 
2013 globally [2]. The chronic effect of hyperglycemia in diabetic condition is 
long been associated with various vascular complications such as stroke, diabetic 
retinopathy, coronary artery disease, diabetic nephropathy, and diabetic 
neuropathy [126]. The resulting clinical complications contribute greatly to the 
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morbidity as well as mortality associated with the diseases; thereby it causes 
serious socio-economic problems [126]. 
The current management for T2DM has mainly focused attention on the 
devastating consequences of protracted hyperglycemia [123, 124]. The available 
treatment options are limited and mainly revolve around oral antidiabetic drugs or 
administration of insulin. These therapeutic options couldn’t resolve T2DM 
completely but helps in the control of the disease by stimulating pancreatic insulin 
secretion, enhancing insulin sensitivity, reducing hepatic gluconeogenesis and 
also absorption of carbohydrates from intestine [125, 126]. During such 
treatments, the patients with T2DM could still become non-responsive to 
medications or become hypoglycemic and suffer from secondary vascular 
complications such as diabetic retinopathy, nephropathy, stroke and 
cardiovascular diseases [127 - 132]. Therefore, the T2DM has to be identified in 
its very early stage(s).  Hence, there is an urgent need for more investigations that 
could lead to the discovery of novel therapeutic approaches to cure T2DM.  
In recent years, the undeniable evidence is becoming apparent between the 
disease status and miRNA expression in patients with Diabetes Mellitus. miRNAs 
are tiny, non-coding RNAs with 20-22 nucleotides that have been implicated in 
the regulation of gene expression. They are also known to participate in a vast 
number of biological processes such as development, metabolism and several 
diseases such as cancer, cardiovascular diseases as well as diabetes [133-136]. 
The primary function of miRNAs is to prevent mRNA translation through 
61 
 
complementary base pairing with the specific sequences in the 3’UTRs [137, 
138]. miRNAs could inhibit the expression of multiple genes and thereby could 
modulate a wide range of regulatory networks across different pathways. This 
provides an alternative option for the diagnosis and treatment of diabetes in the 
early stage of the disease. Therefore, it will be worthwhile to study the miRNA 
expression profiles and its dysregulation during the disease progression. At 
present, there is only a handful of studies on a heterogeneous population or 
patients which show the deregulation of miRNAs in T2DM [139-144]. 
3.2  Clinical features of IFG and T2DM patients 
Adult males (age 21-70yrs) with no previous medical history for diabetes 
or any other diseases were carefully chosen in Alexandra Hospital Singapore for 
health screening throughout the period of July 2008 to April 2009. These 
individuals gave consent to be enrolled for this study. This investigation was also 
permitted by the Institutional Review Board (IRB) (Ministry of health, Singapore; 
MH95:03/1-11) and written consent were obtained from all the individual 
volunteers participated in this study. All participants also undertook a general 
health screening examination including waist and height measurements, blood 
pressure and other anthropometric studies. 
Blood samples collected from these volunteers was then subjected to 
several biochemical tests and the samples were then grouped into 3 distinct 
categories, based on blood glucose level measurements according to World 
Health Organization (WHO) and American diabetes association: a) healthy 
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controls (CTRL, n=7) with fasting glucose < 6.1 mmol/L, b) Impaired Fasting 
Glucose (IFG, n=5) with fasting blood glucose above 6.0 mmol/L but less than 
7.0 mmol/L and c) Type 2 Diabetes Mellitus (T2DM, n=8) with fasting glucose 
greater or equal to 7.0 mmol/L [145]. All the subjects were normotensive (blood 
pressure ≤ 140/90), with appropriate cholesterol levels (LDL ≤ 3.4 mmol/L) and 
body mass index (BMI ≤ 27 which denotes that they were not obese; [97, 145] 
(Table 3.1). For miRNA microarray studies, whole blood samples collected 
separately in tubes containing RNAlater were used. All the subjects in this study 
















 CTRL (n=7) IFG (n=5) T2DM (n=8) 
Age (Years) 46.3±7.5 49.0±7.6 46.7±3.4 
BMI 22.4±2.3 24.1±2.7 24.5±1.1 
Fasting glucose 
≤ 6.0 mmol/L 
4.7±0.7* 6.4±0.1* 8.8±1.9* 
TC 
≤ 5.0 mmol/L 
4.6±0.6 4.7±0.4 4.8±0.2 
LDL 
≤ 3.4 mmol/L 
2.9±0.4 2.9±0.7 3.0±0.3 
SBP 
≤ 140 mmHg 
121.3±11.9 125.8±15.1 125.0±11.2 
DBP 
≤ 90 mmHg 
75.3±9.2 80.4±10.0 79.7±6.4 
Table 3.1: Clinical characteristics of the study and subject demographics. 
Ctrl-Healthy controls with fasting glucose level ≤ 6.0 mmol/L; IFG-Impaired 
Fasting Glucose with fasting glucose level > 6.0 mmol/L but < 7.0 mmol/L; 
T2DM-Type 2 Diabetes Mellitus with fasting glucose level ≥ 7.0 mmol/L; TC –
Total Cholesterol; LDL – Low density Lipoprotein cholesterol; SBP – Systolic 
Blood Pressure; DBP – Diastolic Blood Pressure; Normal values are shown in 
italics. The other measurements mentioned in the table are mean ± Standard 
Deviation (SD). Statistical significance is tested based on t-test - p<0.05 




A total of 20 subjects were selected from 158 individuals recruited for the health 
screening. The selected participants had a mean age of 40.5±9.1 years, fasting 
glucose level 5.1±1.3 mmol/L, SBP 129.0 ±15.1 mmHg and DBP 82.2 ±9.6 
mmHg. For this study, a group of 20 age-matched subjects were selected and 
grouped into three categories namely: Control (CTRL) – n=7, Impaired Fasting 
Glucose (IFG) – n=5 and Type 2 Diabetes Mellitus (T2DM) – n=8. The 
participant’s demographics are shown in Table 3.1.  
3.3 miRNA expression profiles in human blood samples 
 To understand the changes in miRNA expression pattern in healthy 
individuals as well as those with prediabetes and type 2 diabetes mellitus, miRNA 
microarray was performed on the RNAs that were extracted from the blood 
samples that were preserved in RNA later [97].  
3.3.1 microRNA profiles in IFG, and T2DM  
 It is known that miRNAs could function as potential indicators of various 
stages during any disease progression [146-149]. Therefore to understand the 
relevance of circulating blood miRNA expression in IFG and T2DM, miRNA 
microarray data that were published from our laboratory [97] were re-analyzed 
(GEO Accession No GSE21321; SuperSeries GSE26168) after filtering the 
miRNAs with background subtracted mean signal intensities ≥300. miRNAs that  
show at least 1.2 fold change in expression were taken into consideration. A total 
of 178 differentially expressed miRNAs were detectable when impaired fasting 
glucose (IFG) and type 2 diabetes mellitus(T2DM) patients’ blood miRNA 
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profiles were compared with those from the healthy individuals (as controls). 
Figure 3.1 shows the results as a hierarchical clustering plot (heatmap) generated 
using TM4 – MeV (MultiExperiment Viewer) v4.9. The heat map shows that the 
IFG samples are grouped together and segregated well from the T2DM samples. 
Among the miRNAs that showed significant changes in expression as compared 
to control (p<0.05), four different groups of miRNAs could be identified. They 
are: Group I (27 miRNAs) - miRNAs which are upregulated in both IFG and 
T2DM (Figure 3.2), Group II (70 miRNAs) - miRNAs that show down-regulation 
in both IFG and T2DM (Figure 3.3), Group III (49 miRNAs) - miRNAs that are 
downregulated in IFG but upregulated in T2DM (Figure 3.4) and Group IV (32 
miRNAs) - miRNAs that show an opposite pattern to group III, upregulated in 
IFG but downregulated in T2DM (Figure 3.5). These miRNAs could provide 
information about the disease progression from healthy individuals to IFG and 


























Figure 3.1: Hierarchical clustering plot (heat map) of miRNA profiles of human 
IFG and T2DM. Human miRNA expression profile based on IFG and T2DM. 
miRNAs with background subtracted mean signal intensities ≥ 300 are included. 
Data are expressed as fold change. Red represents up-regulation; green indicates 
down-regulation and grey – not detected. IFG – Impaired Fasting Glucose; T2DM 


































Figure 3.2: miRNAs representing Group I. miRNAs with background subtracted 
mean signal intensities ≥ 300 are included. Heat map of selected miRNAs 
dysregulated in human IFG and T2DM and normalized against healthy 
individuals as controls. Data are expressed as fold change with respect to control 
samples. Red represents up-regulation; green indicates down-regulation and grey 










































Figure 3.3: miRNAs representing Group II. miRNAs with background 
subtracted mean signal intensities ≥ 300 are included. Heat map of selected 
miRNAs dysregulated in human IFG and T2DM and normalized against healthy 
individuals as controls. Data are expressed as fold change with respect to control 
samples. Red represents up-regulation; green indicates down-regulation and grey 







































Figure 3.4: miRNAs representing Group III. miRNAs with background 
subtracted mean signal intensities ≥ 300 are included. Heat map of selected 
miRNAs dysregulated in human IFG and T2DM and normalized against healthy 
individuals as controls. Data are expressed as fold change with respect to control 
samples. Red represents up-regulation; green indicates down-regulation and grey 






















Figure 3.5: miRNAs representing Group IV. miRNAs with background 
subtracted mean signal intensities ≥ 300 are included. Heat map of selected 
miRNAs dysregulated in human IFG and T2DM and normalized against healthy 
individuals as controls. Data are expressed as fold change with respect to control 
samples. Red represents up-regulation; green indicates down-regulation and grey 





3.4 miRNA expression profiles in rat model of T2DM 
 As the patient’s sample size reported by Karolina et al, [97] was relatively 
small, the blood miRNA profiles of rat T2DM (GEO Accession No: GSE26167; 
SuperSeries: GSE26168) were included in the analysis to improve the 
discriminative power of this study. The T2DM model in rats was created by 
feeding the animals with high fat diet (HFD) and a low dosage of Streptozotocin 
(STZ) as it is known to be a better approach to initiate insulin resistance with 
steady progress in the hyperglycemia and eventually T2DM. The oral glucose 
tolerance test (OGTT) was performed on each rat at the end of the treatment 
regime and serum glucose and insulin levels were measured after OGTT. The 
results showed there were an increase in the serum glucose level and a decrease in 
insulin sensitivity in high fat diet-induced rats (Table 3.2). 
Factors 







Weight 204.67 ± 4.55 211.67 ± 3.78 336.33 ± 5.58 359.33 ± 8.03* 
Glucose 
(mmol/L) 
8.27 ± 0.74 8.93 ± 0.26 11.53 ± 1.23 30.08 ± 3.45* 
Insulin 
(mU/L) 
0.11 ± 0.01 0.10 ± 0.00 0.13 ± 0.00 0.33 ± 0.02* 
Table 3.2: Factors measured in control and treated rats. 
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To identify commonly dysregulated miRNAs during the disease progression of 
T2DM in rats, the miRNA microarray data were analyzed with the same filtering 
criteria that were used for human microarray data with signal intensities of ≥ 300. 
Only miRNAs that are conserved between human and rat have been taken into 
consideration. To understand more about the miRNAs that are dysregulated in 
T2DM, the results from in vivo model of HFD-low dosage of STZ induced T2DM 
rats were compared with results from human IFG and T2DM. The miRNAs that 
did not show similar expression pattern between human and rat were discarded. 
After comparison with a rat model of T2DM, a total of about 52 miRNAs that are 
dysregulated in T2DM and conserved between human and rat have been 
identified. The results were again categorized into four different groups as 
mentioned earlier in human studies. a) Group I (15 miRNAs): miRNAs which are 
upregulated in both IFG and T2DM (Figure 3.6-i). b) Group II (17 miRNAs): 
miRNAs showed down-regulation in both IFG and T2DM (Figure 3.6-ii). c) 
Group III (10 miRNAs): miRNAs that were downregulated in IFG but 
upregulated in T2DM (Figure 3.6-iii) and d) Group IV (10 miRNAs): miRNAs 
that showed a contrasting pattern to group III as upregulated in IFG but 
downregulated in T2DM (Figure 3.6-iv).  All 52 miRNAs showed significant 
changes (p<0.05). This indicates that the miRNA expression profiles in IFG and 
T2DM could provide information about the disease progression from healthy 



















Figure 3.6: Heatmap of selected 52 miRNAs dysregulated in human and rat 
T2DM. miRNAs that showed differential expression are grouped into 4 categories 
(i to iv). miRNAs that remained: (i) upregulated in both IFG and T2DM against 
controls, (ii) downregulated in both IFG and T2DM, (iii) downregulated in IFG 
but upregulated in T2DM, (iv) upregulated in IFG but downregulated in T2DM. 
Data are expressed as fold change. Red represents up-regulation; green indicates 












3.5 Bioinformatics pathway prediction for the dysregulated miRNAs and       
mRNA in T2DM 
Among the 52 miRNAs that were found to be conserved between human and rat 
T2DM, 25 miRNAs that were upregulated in groups 1 & 3 and 27 miRNAs that 
were downregulated in groups 2 & 4 (Figure 3.6), were selected for subsequent 
analysis.  KEGG pathway analysis was carried out on these miRNAs using two 
independent databases, DIANA miRpath 2.0 [115] and miRWalk version 2.0 
[116]. The selection criteria used were microT threshold value of 0.8 and cutoff of 
p <0.05. The results showed a total of 2948 genes regulating more than 100 
significant pathways (p <0.05). This is rather expected since a single miRNA has 
the ability to control the expression of more than 100 genes. Subsequently, the 
results were further streamlined by focusing on the top 20 pathways that were 










Table 3.3: Bioinformatics prediction - DIANA-miRPath 2.0 KEGG pathway 
analysis. Commonly upregulated 25 miRNAs in human and rat T2DM 
S.no KEGG Pathway p-value genes miRNAs 
1. Regulation of actin 
cytoskeleton  
1.30e-33 109 25 
2. Focal adhesion  4.38e-30 99 25 
3. Endocytosis  8.28e-16 93 25 
4. Axon guidance  6.01e-29 72 25 
5. Pathways in cancer  4.72e-39 165 24 
6. P13K-Akt  signaling 
pathway  
1.42e-29 154 24 
7. MAPK signaling pathway  7.23e-19 118 24 
8. Wnt signaling pathway  3.05e-27 81 24 
9. Ubiquitin mediated 
proteolysis  
6.33e-25 68 24 
10. Neurotrophin signaling 
pathway  
2.98e-26 65 24 
11. TGF-beta signaling 
pathway  
2.26e-24 55 24 
12. Apoptosis 2.00e-21 53 23 
13. Chronic myeloid leukemia  6.76e-18 43 23 
14. Renal cell carcinoma  5.64e-17 40 23 
15. Long term potentiation  8.28e-16 40 23 
16. Melanoma  8.28e-16 38 23 
17. Gap junction  1.35e-14 45 21 
18. Gastric acid secretion  1.23e-15 39 21 
19. mTOR signaling pathway  1.13e-14 37 21 





S.no KEGG Pathway p-value genes miRNAs 
1. MAPK signaling pathway  1.85e-30 130 24 
2. Neurotrophin signaling 
pathway  
1.41e-29 71 24 
3. Wnt signaling pathway  6.72e-37 84 23 
4. Apoptosis  6.24e-21 50 23 
5. P13K-Akt  signaling 
pathway  
4.80e-64 169 22 
6. Pathways in cancer  4.18e-42 166 22 
7. Focal adhesion  2.27e-41 102 22 
8. Regulation of actin 
cytoskeleton  
1.37e-20 101 22 
9. Ubiquitin mediated 
proteolysis  
4.95e-21 68 22 
10. Dopaminergic synapse  1.53e-22 67 22 
11. Prostate cancer  4.55e-23 55 22 
12. Gap junction  1.04e-21 47 22 
13. Phosphatidylinositol 
signaling system  
2.74e-20 47 22 
14. Insulin signaling system  1.30e-28 70 21 
15. Small cell lung cancer  1.89e-20 49 21 
16. ErbB signaling pathway  5.49e-21 48 21 
17. TGF-beta signaling pathway  2.48e-21 47 21 
18. Renal cell carcinoma  7.10e-20 41 21 
19. Chronic myeloid leukemia  2.05e-19 43 21 
20. p53 signaling  4.38e-19 44 19 
Table 3.4: Bioinformatics prediction - DIANA-miRPath 2.0 KEGG pathway 
analysis. Commonly downregulated 27 miRNAs in human and rat T2DM 
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Likewise, to understand better about the disease progression during 
T2DM, mRNA microarray was also performed (GEO accession no. GSE21321; 
SuperSeries GSE26168) on the respective human blood samples which were used 
for human IFG and T2DM miRNA microarray [97]. The human blood samples 
consists of both IFG (n = 5) and T2DM (n = 8) (under Section 3.2). The 
background-subtracted mean intensity of >300 was selected as a threshold value 
and normalized against U6 snRNA. The data was converted into fold change and 
>1.2 fold was considered for the KEGG pathway analysis using Webgestalt 
database [117]. Top 20 pathways with p<0.05 were represented in Table 3.5 Both 
mRNA and miRNA microarrays indicated that the key pathways that have been 
commonly dysregulated during T2DM disease progression included regulation of 
actin cytoskeleton pathway, PI3K-Akt signaling pathway, focal adhesion 
pathway, apoptosis, Wnt signaling pathway, Neurotrophin signaling pathway, 
MAPK signaling pathway, TGF-beta signaling pathway, mTOR signaling 
pathway, and Insulin signaling system. Some of these pathways have been 
reported to be associated with either T2DM or its diabetes-related vascular 
complications during disease progression (Figure 3.7; Table 3.5). Hence, these 
dysregulated pathways and the 52 miRNAs involved in their regulation could 
serve as potential biomarkers for identification of diabetes from its very early 










Table 3.5: Bioinformatics prediction – Webgestalt KEGG pathway analysis. 
Top 20 Commonly dysregulated mRNA pathways in IFG and T2DM (Fold 
change ± ≥ 1.2 with significant p-value < 0.01) 
S.no KEGG Pathway Gene p-value 
1. Metabolic pathways 868 5.67e-236 
2. Type II diabetes mellitus 378 5.18e-141 
3. Pathways in cancer 320 8.21e-123 
4. Cytokine-cytokine receptor interaction 257 4.09e-94 
5. Neuroactive ligand - receptor 
interaction 
259 4.36e-89 
6. MAPK signaling pathway 254 4.45e-86 
7. Focal adhesion  192 7.13e-68  
8. Regulation of actin cytoskeleton 199 2.16e-64  
9. Endocytosis 189 1.83e-62  
10. Chemokine signaling pathway 180 4.58e-62 
11. Calcium signaling pathway 171 6.05e-62 
12. Huntington’s disease  163 6.71e-46 
13. Purine metabolism 151 1.04e-48 
14. Jak-STAT pathway 153 4.35e-60 
15. Wnt-signaling pathway 147 3.91e-56 
16. Phagosome  146 8.91e-51  
17. Ubiquitin mediated proteolysis 130 1.13e-46 
18. Insulin signaling pathway 132 2.36e-46 
18. Neurotrophin signaling pathway 121 3.85e-42 
19. Cell adhesion molecules (CAMs) 127 1.71e-44  










Figure 3.7: Venn diagram representing commonly dysregulated pathways based 
on miRNA and mRNAs microarray data analysis. 
3.6  Biological pathway correlation with their gene target related to 
diabetes and its vascular complications 
The results obtained from the pathway analysis of dysregulated miRNAs 
(Table 3.3 & 3.4) and mRNAs (Table 3.5) has been compared which showed 10 
common pathways that were dysregulated and had been reported to associate with 
T2DM and its related vascular complications. Since the selected miRNAs and 
their target genes such as RHOA, ROCK2, RAC1, BCL2, MCL1 and CASP3 
(Table 3.6) that are implicated in T2DM related pathways are also involved in 
endothelial dysfunction; a further objective of the study could be to understand 
the contribution of endothelial dysfunction to the disease progression. Therefore, 
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RHOA - ras homolog family 
member A) 
ROCK1 - rho-associated, coiled-coil 
containing protein kinase 1  
RAC1 - ras-related C3 botulinum 
toxin substrate 1 (rho family, small 
GTP binding protein Rac1)  
PAK 1 - p21 protein (Cdc42/Rac)-
activated kinase 1 
Loss of cortical actin filaments 
impairs GLUT4 vesicle 




Selective inhibition of Rac-1 




Activation of ROCK during 




dysregulation of small GTPases 
such as Rac-1, Rho, ROCK, 
CDC42 are involved in 







PIK3CA - phosphatidylinositol-4, 5-
bisphosphate 3-kinase, catalytic 
subunit alpha 
AKT/PKB – protein kinase B 
PTEN - phosphatase and tensin 
homolog  
FOXO1 - forkhead box O1 
Hyperglycemia alters PI3K-





PI3K-Akt signaling causes 
proliferative diabetic 
retinopathy and its inhibition 





activation of microvascular 





FAK – focal adhesion kinase 
SRC - SRC proto-oncogene, non-
receptor tyrosine kinase  
PXN - paxillin  
Focal adhesion remodeling 
(FAK and PXN) involves in the 
insulin signaling and glucose 




FAK induced vascular 
permeability via activation of 
SRC in diabetic condition 
[160]
 
Apoptosis BCL2 – B-cell CLL/lymphoma 2 
MCL1 - myeloid cell leukemia 1 
XIAP - X-linked inhibitor of 
apoptosis, E3 ubiquitin protein ligase 
CASP3 - caspase 3, apoptosis-related 
cysteine peptidase 
MSTI in the apoptotic pathway 




Vascular complications in 
diabetes are due to imbalance 












TCF7L2 - transcription factor 7-like 
2 (T-cell specific, HMG-box) 
SHC1 - (Src homology 2 domain 
containing) transforming protein 1 
Wnt signaling plays a crucial 
role in the function of 




Canonical wnt signaling 
requires p66Shc and it involves 
in the endothelial dysfunction 
and wnt signaling also involves 







CNTF – Ciliary neurotrophic growth 
factor 
BDNF - brain-derived neurotrophic 
factor 
NGFR – Nerve growth factor 
receptor 
NTRK1 - neurotrophic tyrosine 
kinase, receptor, type 1 
Protects against T2DM by 
increasing beta cell mass and 
delays insulin clearance 
[166]
 
Low level of BDNF has been 




During T2DM, Neurotrophin 
p75 receptor promotes 







KRAS - kirsten rat sarcoma viral 
oncogene homolog,  
MAPK1 – mitogen-activated protein 
kinase 1 
CREB1 – cAMP responsive element 
binding protein 1  
MAPK8 - mitogen-activated protein 
kinase 8 
MAPK14 - mitogen-activated protein 
kinase 14 
Increase in MAPK signaling 
impairs endothelial cell 
signaling in T2DM 
[169]
 
MAPK signaling plays 








TGFBRII - transforming growth 
factor, beta receptor II 
SMAD3/4 - SMAD family member 3 
Knockdown of TGF-β/SMAD3 
protects again high fat diet-







RAPTOR - regulatory associated 
protein of MTOR, complex 1,  
RICTOR - RPTOR independent 
companion of MTOR, complex 2 







IRS1/2 - insulin receptor substrate 
1/2  
PKCZ - protein kinase C, zeta 
PDK1 - pyruvate dehydrogenase 
kinase, isozyme 1 
SLC2A4 - solute carrier family 2 
(facilitated glucose transporter), 
member 4 
Dysregulation of insulin 
signaling causes insulin 
resistance and impaired glucose 
uptake and metabolism 
[177, 178]
 
Table 3.6: Commonly dysregulated top 10 pathways during IFG and T2DM 








miRNAs in hyperglycemia induced 
endothelial cell apoptosis 
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4.    miRNAs in hyperglycemia induced endothelial cell apoptosis 
4.1 Introduction 
Healthy endothelial cells (EC) are quiescent, flat and monolayer of cells that 
wraps the internal lumen of all vasculature and serves as an interface between 
circulating blood and vascular smooth muscle cells (VSMCs) [179]. ECs bound to 
one another through tight junctions (zona occludens) and adherens junctions (zona 
adherens). They communicate with neighboring cells through gap junctions also 
known as connexins, which act as channels for intercellular exchange of ions and 
small molecules [180]. The continuous endothelium lining the blood vessels and 
acts as a gatekeeper for the selective passage of plasma proteins, solutes and fluid 
from the blood to the underlying interstitium and cells [181]. The EC responds to 
various humoral, neural and mechanical stimuli and secretes various autocrine as 
well as paracrine vasoactive chemical mediators including nitric oxide (NO), 
endothelin – 1, angiotensin II (ANG-II), tissue-type plasminogen activator (t-PA), 
plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor (vWF), 
adhesion molecules (VCAM, ICAM, PE-CAM), and cytokines, Tumor Necrosis 






According to IDF (International Diabetic Federation) 2014, every year 5.1 million 
people are dying due to diabetes or diabetes-related vascular complication [2]. 
Hyperglycemia in diabetes is known to be a major contributing factor for 
endothelial dysfunction during micro and macrovascular disease such as diabetic 
retinopathy, nephropathy and ischemic stroke [184-186]. The continuous 
exposure of ECs to chronic hyperglycemia in the blood during diabetic condition 
will alter its quiescence state and impair normal function. The continuous changes 
in glucose levels increase the degree of endothelial cell damage [187, 188]. 
Endothelial dysfunction is characterized by a deficiency in the bioavailability of 
nitric oxide, enhanced endothelial permeability, an imbalance in vasoactive 
agent’s synthesis, elevated leukocyte adhesion molecule expression and reduced 
antithrombotic properties, increased permeability of molecules and cell death 
(Figure 4.1) [189, 190]. Recently, the mechanism underlying endothelial function 
in vascular biology has gained much attention, particularly on its implications in 













Figure 4.1: Endothelial cells in vascular homeostasis. Diagrammatic 
representation of healthy and unhealthy endothelial cells in the regulation of 
various biological processes in the vascular homeostasis 
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The current biomarkers such as C-reactive protein (CRP), P-selectin, E-selectin, 
Von Willebrand factor (VWF), Interleukin 6 (IL-6), Chemokine C-C motif ligand 
2 (CCL2), Vascular cell adhesion molecule 1 (VCAM-1), Intercellular adhesion 
molecule 1 (ICAM-1) could only detect endothelial dysfunction after the disease 
has progressed to advanced stages [191]. Most of the current techniques which 
monitor variations in glucose levels are either less reliable or inaccurate and these 
cannot quantify the degree of endothelial cell damage [192, 193]. Hence, there is 
a need to identify potential biomarker(s) that can be sensitive enough to detect 
small changes in the glucose level of blood as well as to predict endothelial 
dysfunction in very early stages of the disorder.  
miRNAs could be the potential biomarker to detect endothelial dysfunction. A 
total of 2588 miRNAs (miRbase version 21) have been identified thus far in the 
human genome and they control more than 30 – 60 % of the total protein-coding 
genes [194, 195]. The importance of miRNAs in EC function and blood vessel 
development was discovered by disrupting the function of two RNase III 
enzymes, dicer and drosha that are required for miRNA biogenesis [196, 197]. 
From then onwards, researchers became interested in understanding the molecular 
mechanisms underlying miRNA-based regulation of gene expression in diabetes 
and other vascular complications that are related to endothelial dysfunction [198-
202]. Interestingly, the conception of miRNAs as intracellular mediators of gene 
expression has now been changed to intercellular signaling molecules. Moreover, 
Mitchell et al, [84] showed that circulatory miRNAs are resistant to degradation 
by endogenously produced RNAse and are remarkably stable under various harsh 
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conditions such as multiple freeze- thaw cycles, boiling, and low or high pH. 
These paved a new way for miRNAs as intercellular signaling molecules and 
potential diagnostic markers for vascular dysfunction [198-202]. With regards to 
the miRNAs as potential indicators of endothelial apoptosis due to hyperglycemia 
only two miRNAs: miR-21 and miR-126 have so far been reported [203,204]. 
Therefore, this chapter has been attempted to identify miRNAs that could function 
in predicting endothelial dysfunction associated with apoptosis that are commonly 
induced by hyperglycemia. 
4.2 Cell viability assay 
In order to identify the effect of hyperglycemia upon endothelial cells, in vitro 
model was set up and Human Umbilical Vein Endothelial Cells (HUVECs) were 
subjected to a different concentration of glucose treatment (5, 10, 25, 40 mM) at 
various time intervals (6 hrs, 12 hrs, 24 hrs, and 48 hrs). MTT assay was 
performed to measure the cell viability. The data from MTT assay showed that as 
glucose level increased from that of control (5 mM), the cell viability decreased 
by 0.6, 11.37 and 14.8% at 10, 25 and 40 mM glucose respectively after 24 hrs of 
incubation. The cell viability further decreased (2.9, 14.5 21.4 % for 10, 25 and 40 
mM glucose treatments respectively) when incubation time was prolonged up to 












Figure 4.2: Cell viability assay. HUVECs were subjected to different 
concentrations of glucose at a different time interval and 4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide (MTT) activity was measured to observe 
endothelial viability. Each experiment was carried out in triplicates and in sets of 
three independent experiments (n=3). Data presented as mean ± SEM. * indicates 
statistical significance student – t-test, p < 0.05.  
4.3 Cytotoxicity assay 
Consistent with reduction in endothelial cell viability, the lactate dehydrogenase 
(LDH) that was released into the respective cell culture medium showed that the 
endothelial cytotoxicity increases with increase in glucose treatment at different 
time intervals (Figure 4.3). Since both cell viability and cytotoxicity shows that 
there is an increase in cell death upon glucose treatment, therefore it is a 
necessary to measure the glucose level inside and outside of the cell which could 
have caused the cell death.  


















Figure 4.3: Cytotoxicity assay (Figure needs to be changed). HUVECs were 
subjected to different concentrations of glucose at a different time interval and 
LDH activity was measured to observe endothelial cytotoxicity. Each experiment 
was carried out in triplicate and in sets of three independent experiments (n=3). 
Data presented as mean ± SEM. * indicates statistical significance student – t-test, 







4.4 Glucose uptake measurement assay 
In order to verify that the glucose concentrations within the cells do vary in 
accordance with the changes in the external concentrations of glucose, the 
intracellular levels of glucose corresponding to each treatment (5 to 40 mM) were 
measured. The results showed that there was an increasing trend in glucose 
concentration within the cells: 2.90, 6.55, 13.37 and 25.20 mM for 5, 10, 25 and 
40 mM glucose treatments respectively (Figure 4.4). Concurrently the residual 
glucose concentration was also measured in the culture media. From the results, 
as expected, it is clear that a fraction of the total glucose in the medium has been 
metabolized as well. 
 
Figure 4.4: HUVECs subjected to various glucose treatments. Glucose uptake 
measurement assay. ICG – Intracellular Glucose; ECG – Extracellular Glucose. 
Cells and media were collected at 6, 12, 24 and 48 hrs. Each experiment was 
carried out in triplicate and in sets of three independent experiments (n=3). Data 




4.5 miRNA profiles in HUVECs - in vitro model of T2DM  
As miRNAs showing dysregulation during pathophysiological conditions have 
been linked to the gene and consequently protein expression in cells, it was 
postulated that miRNAs responding to changes in glucose concentrations could 
possibly be involved in pathways leading to apoptosis and endothelial 
dysfunction. Thus, miRNA microarray was performed on HUVECs treated with 
various glucose concentrations (5 to 40 mM) and at various time-points (6 to 48 
hrs). The microarray data with raw signal intensity values and normalized data 
have been deposited at the NCBI database under the GEO accession no: 
GSE74296, GPL21059. Among these miRNAs that are normalized to endogenous 
controls, 177 miRNAs (with a signal intensity >300) that were commonly 
dysregulated in all time points could be identified. The hierarchical clustering of 
these miRNAs showed that miRNA expression pattern changes in all the glucose 
treatments (Figure 4.5). Among them, a total of 62 miRNAs showed a gradual 




















Figure 4.5: Hierarchical clustering of miRNAs in HUVECs subjected to different 
glucose treatments and time intervals. Glucose concentrations at 5, 10, 25 and 40 
mM for 6, 12, 24 and 48 hrs have been used in the study.  177 miRNAs with 
background subtracted mean signal intensities ≥ 300 are included. Data are 
expressed as logarithm of raw intensity values where green represents low signal 
intensity and red represents high signal intensity. 





hsa-miRNA 5 mM 10 mM 25 mM 40 mM 
Glucose treatment for 6 hrs 
1 miR-1260a 1.00 1.49 1.95 2.33 
2 miR-1270 1.00 2.03 2.42 3.80 
3 miR-20b-5p
#
 1.00 1.96 2.05 2.23 
4 miR-376a-3p 1.00 1.80 1.91 2.11 
5 miR-570-3p
#
 1.00 1.19 3.40 5.48 
6 miR-616-3p 1.00 1.20 1.69 2.91 
 Glucose treatment for 12 hrs 
7 miR-1267 1.00 1.38 2.39 2.59 
8 miR-1284 1.00 1.32 1.35 1.56 
9 miR-1304-5p 1.00 1.41 1.54 1.60 
10 miR-133b
#
 1.00 1.12 1.24 1.43 
11 miR-148a-5p
#
 1.00 1.06 1.57 1.66 
12 miR-148b-3p 1.00 1.07 1.19 1.36 
13 miR-183-3p 1.00 1.07 1.23 1.28 
14 miR-198 1.00 1.33 1.77 1.93 
15 miR-203a 1.00 1.13 1.88 1.54 
16 miR-22-5p 1.00 1.26 2.05 2.09 
17 miR-221-5p 1.00 1.20 1.60 1.63 
18 miR-23a-5p 1.00 1.28 2.11 2.24 
19 miR-29b-1-5p 1.00 1.43 1.58 1.61 
20 miR-320a
#
 1.00 1.27 1.44 1.76 
21 miR-320b 1.00 1.13 1.22 1.39 
22 miR-320c 1.00 1.15 1.38 1.43 






hsa-miRNA 5 mM 10 mM 25 mM 40 mM 
Glucose treatment for 24 hrs 
24 miR-1183 1.00 1.25 2.17 3.88 
25 miR-1227-3p 1.00 1.62 1.80 2.98 
26 miR-1252-3p 1.00 1.91 2.10 2.85 
27 miR-125b-1-3p
#
 1.00 1.04 1.11 1.27 
28 miR-1262 1.00 1.40 1.65 2.63 
29 miR-1266-5p 1.00 1.07 2.70 4.72 
30 miR-130b-3p
#
 1.00 1.26 1.53 2.27 
31 miR-132-5p 1.00 1.26 1.61 2.40 
32 miR-133a-3p 1.00 1.34 1.39 1.76 
33 miR-140-5p
#
 1.00 1.28 1.44 2.65 
34 miR-148a-5p
#
 1.00 1.36 1.44 1.89 
35 miR-181a-3p 1.00 1.07 1.12 1.51 
36 miR-181a-2-3p 1.00 1.31 1.40 2.50 
37 miR-187-5p 1.00 1.17 1.20 1.81 
38 miR-192-5p
#
 1.00 1.26 1.45 1.97 
39 miR-20b-5p
#
 1.00 1.56 1.68 1.81 
40 miR-219a-1-3p 1.00 1.87 1.88 2.81 
41 miR-221-3p
#
 1.00 1.11 1.27 1.41 
42 miR-222-3p 1.00 1.06 1.11 1.52 
43 miR-26a-5p
#
 1.00 1.13 1.27 1.84 
44 miR-26b-5p
#
 1.00 1.10 1.23 1.44 
45 miR-29b-3p
#
 1.00 1.25 1.69 2.42 
46 miR-29c-3p
#
 1.00 1.26 1.86 2.65 
47 miR-320a
#
 1.00 1.38 1.59 1.81 
48 miR-34c-5p 1.00 1.85 2.29 4.60 
49 miR-376b-3p 1.00 1.29 1.44 1.73 
50 miR-502-5p 1.00 1.12 1.39 2.10 
51 miR-518a-5p 
/ miR-527 1.00 1.08 1.35 2.33 
52 miR-519e-3p 1.00 1.13 1.42 2.23 
53 miR-570-3p
#
 1.00 1.76 2.33 6.40 
54 miR-573 1.00 2.11 2.40 6.03 
55 miR-611 1.00 1.69 1.89 3.50 




Table 4.1: miRNA microarray results from HUVECs cells subjected to different 
hyperglycemic conditions and treatment intervals. Fold change values with 
Pearson correlation coefficient |R| > 0.8 and statistical significance (student t-test; 
p<0.05) in expression are shown below. The values were normalized against 
control where the cells were treated with 5 mM glucose for different time 
intervals. Of the 76 miRNAs listed below, 62 miRNAs have been found to be 
differentially expressed in more than one-time point. These miRNAs have been 
indicated with #. 
 
 Glucose treatment  for 48 hrs  
hsa-miRNA 5 mM 10 mM 25 mM 40 mM 
57 miR-125b-1-3p
#
 1.00 1.12 1.22 1.57 
58 miR-130b-3p
#
 1.00 1.58 1.92 2.68 
59 miR-133a-5p 1.00 1.14 1.38 1.81 
60 miR-133b
#
 1.00 1.01 1.13 1.70 
61 miR-140-5p
#
 1.00 1.79 1.95 3.10 
62 miR-15b-5p 1.00 1.11 1.32 1.74 
63 miR-17-3p 1.00 1.11 1.28 1.79 
64 miR-181a-5p 1.00 1.12 1.42 1.81 
65 hsa-miR-181b-5p 1.00 1.10 1.50 1.66 
66 hsa-miR-18b-5p 1.00 1.26 1.38 1.74 
67 hsa-miR-192-5p
#
 1.00 1.21 1.87 2.41 
68 hsa-miR-19a-3p 1.00 1.16 1.26 1.43 
69 hsa-miR-19b-3p 1.00 1.21 1.22 1.59 
70 hsa-miR-21-5p 1.00 1.08 1.13 1.93 
71 hsa-miR-221-3p
#
 1.00 1.38 1.97 4.30 
72 hsa-miR-26a-5p
#
 1.00 1.30 1.55 2.12 
73 hsa-miR-26b-5p
#
 1.00 1.22 1.42 2.24 
74 hsa-miR-29b-3p
#
 1.00 1.35 2.19 2.86 
75 hsa-miR-29c-3p
#
 1.00 1.44 2.21 3.25 
76 hsa-miR-320a
#





4.6  Bioinformatics pathway prediction 
In order to identify the pathways dysregulated due to the 62 miRNAs that were 
gradually upregulated during high glucose treatment, in silico analysis was 
performed using miR-path 2.0 [115]. The KEGG pathway prediction showed that 
more than 100 significant pathways are dysregulated with p-value <0.05 and 
stringent cut-off value of microT threshold value 0.8 (Table 4.2). Among them, 
Top 20 pathways were selected (Table 4.2) and compared with the top 20 
pathways that were dysregulated during T2DM in human and rat (Tables 3.3A, 
3.3B and 3.4). The results showed that 10 pathways were common to all three 
cases examined. Hence, they could be potentially involved in various forms of 
endothelial dysfunction. The cellular studies showed that PI3K-Akt signaling 
pathway, p-53 signaling pathway, and apoptosis as among the top 10 pathways. 
This supported the findings from cytotoxicity study under hyperglycemic 
treatments. Hence, hyperglycemia induced endothelial apoptosis was chosen for 




KEGG pathway p-value Genes miRNAs 
Regulation of actin cytoskeleton 3.87E-54 183 55 
PI3K-Akt signaling pathway 1.62E-50 187 54 
p53 signaling pathway 6.52E-32 111 52 
Apoptosis 8.09E-29 92 51 
Focal adhesion 8.09E-29 107 51 
VEGF signaling pathway 5.97E-27 132 54 
Notch signaling pathway 1.30E-25 89 50 
Chemokine signaling pathway 6.04E-24 94 53 
Tight junction 7.76E-21 75 50 
Wnt signaling pathway 1.80E-20 73 50 
Insulin signaling pathway 5.77E-20 73 46 
Neurotrophin signaling pathway 1.87E-19 69 52 
TGF-beta signaling pathway 9.90E-17 54 47 
Cell cycle 1.09E-15 126 55 
Adherens junction 2.70E-15 54 48 
ErbB signaling pathway 2.70E-15 51 50 
MAPK signaling pathway 8.65E-15 51 47 
mTOR signaling pathway 8.65E-15 49 48 
Type II diabetes mellitus 2.04E-14 46 46 
Renal cell carcinoma 2.04E-14 44 47 
Small cell lung cancer 2.68E-14 51 47 
RNA transport 7.19E-14 76 53 
Chronic myeloid leukemia 8.84E-14 47 47 
Melanoma 4.24E-13 45 47 
HIF-1 signaling pathway 4.88E-13 56 48 
GnRH signaling pathway 5.20E-13 46 46 
Salivary secretion 5.20E-13 46 46 
Colorectal cancer 6.65E-12 39 42 
Amoebiasis 9.17E-12 54 47 
Pathways in cancer 1.59E-11 41 43 
Long-term potentiation 1.59E-11 41 43 
RNA degradation 2.12E-11 40 42 
Protein processing in endoplasmic reticulum 2.63E-11 103 51 
Pancreatic cancer 2.76E-11 38 42 
Non-small cell lung cancer 5.13E-11 34 41 
Hepatitis B 6.54E-11 75 55 
Acute myeloid leukemia 3.41E-10 34 44 
Glioma 6.79E-10 41 47 
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Bacterial invasion of epithelial cells 1.10E-09 37 44 
Melanogenesis 1.33E-09 51 44 
Endometrial cancer 3.00E-09 31 42 
Hedgehog signaling pathway 5.50E-09 31 30 
Retrograde endocannabinoid signaling 5.50E-09 57 46 
Glutamatergic synapse 8.96E-09 60 48 
Fc gamma R-mediated phagocytosis 9.90E-09 46 45 
Axon guidance 1.10E-08 66 50 
Cholinergic synapse 1.65E-08 59 47 
Transcriptional misregulation in cancer 2.61E-08 86 53 
Prostate cancer 3.55E-08 33 46 
T cell receptor signaling pathway 4.46E-08 52 49 
mRNA surveillance pathway 6.33E-08 26 37 
B cell receptor signaling pathway 1.28E-07 38 47 
Calcium signaling pathway 2.70E-07 83 48 
Phosphatidylinositol signaling system 3.00E-07 46 49 
Long-term depression 3.18E-07 37 40 
Protein digestion and absorption 3.88E-07 42 37 
Bladder cancer 1.06E-06 23 32 
Aldosterone-regulated sodium reabsorption 1.06E-06 23 37 
Pathogenic Escherichia coli infection 1.23E-06 27 37 
Adipocytokine signaling pathway 1.95E-06 34 39 
Dilated cardiomyopathy 2.78E-06 43 41 
Circadian rhythm 5.15E-06 19 30 
Endocrine and other factor-regulated calcium 
reabsorption 
9.50E-06 28 39 
Thyroid cancer 9.63E-06 16 31 
Mineral absorption 1.24E-05 25 34 
Endocytosis 1.31E-05 23 27 
Ubiquitin mediated proteolysis 1.70E-05 64 47 
Basal cell carcinoma 2.85E-05 27 34 
Vascular smooth muscle contraction 3.82E-05 57 49 
Epstein-Barr virus infection 3.82E-05 94 54 
Epithelial cell signaling in Helicobacter pylori 
infection 
5.87E-05 32 35 
Protein export 0.00012 15 23 
HTLV-I infection 0.000131 62 43 
Inositol phosphate metabolism 0.000144 30 42 
Progesterone-mediated oocyte maturation 0.000185 39 43 
Oocyte meiosis 0.000204 60 48 
ABC transporters 0.000253 21 25 
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Osteoclast differentiation 0.000254 58 48 
Dorso-ventral axis formation 0.000292 14 29 
Chagas disease (American trypanosomiasis) 0.000292 48 48 
Hepatitis C 0.000292 58 45 
Sphingolipid metabolism 0.000658 25 34 
Nicotine addiction 0.001043 24 38 
Gastric acid secretion 0.00116 34 38 
Glycosaminoglycan biosynthesis - heparin 
sulfate / heparin 
0.001245 15 26 
Dopaminergic synapse 0.001958 39 42 
Shigellosis 0.002019 28 40 
Carbohydrate digestion and absorption 0.002713 20 32 
Salmonella infection 0.003075 38 42 
Hypertrophic cardiomyopathy (HCM) 0.003667 37 37 
Lysosome 0.00437 55 42 
Fatty acid biosynthesis 0.004758 3 2 
Measles 0.005009 62 50 
GABAergic synapse 0.005594 46 49 
Lysine degradation 0.007109 25 43 
Amyotrophic lateral sclerosis (ALS) 0.007802 25 35 
Synaptic vesicle cycle 0.036459 32 36 
Prion diseases 0.038919 12 29 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
0.040867 35 38 
Vibrio cholerae infection 0.042775 23 29 
Biotin metabolism 0.046389 2 4 
 Table 4.2: Bioinformatics pathway prediction: Significantly dysregulated KEGG 




4.7 Nuclear morphology assessment by DAPI staining 
Ho et al, [205] and Ido et al, [206] reported that hyperglycemia induced decrease 
in EC viability is associated with endothelial apoptosis. The results of MTT and 
LDH assays are also consistent with their observations. In order to identify 
whether the endothelial cells underwent apoptosis, their nuclear morphology was 
examined after staining with DAPI (Hoescht 33342) and the images were 
captured using Olympus IX51 microscope. Healthy nuclear morphology was 
observed in 5 mM glucose treatment across all time intervals (6-48 hrs) whereas 
the cells treated with higher concentrations of glucose (25 mM and 40 mM 
glucose) showed significant changes in nuclear morphology such as shrunken, 
fragmented or pyknotic nuclei (Figure 4.6 – 4.9). Apparently the observed 
changes in nuclear morphology for short term treatments (6 and 12 hrs) were not 
statistically significant (p<0.05). In each concentration of glucose treatment, the 
captured images of approximately 100 – 120 cells were counted and percentages 










      
      
Figure 4.6: Fluorescence microscopy for DAPI nuclear staining. Cells were 
subjected to different glucose treatments (5-40 mM) and collected at 6 hrs time 
interval. The images were captured using Olympus IX51 microscope (objective 
20x magnification) with scale bar of 200 µm. Healthy nuclei can be observed for 
5mM glucose treatments. A significant amount of Shrunken/fragmented and 
pyknotic nuclei can be seen only under hyperglycemic conditions.  
 




        
      
Figure 4.7: Fluorescence microscopy for DAPI nuclear staining. Cells were 
subjected to different glucose treatments (5-40 mM) and collected at 12 hrs time 
interval. The images were captured using Olympus IX51 microscope (objective 
20x magnification) with scale bar of 200 µm. Healthy nuclei can be observed for 
5mM glucose treatments. A significant amount of Shrunken/fragmented and 









    
Figure 4.8: Fluorescence microscopy for DAPI nuclear staining. Cells were 
subjected to different glucose treatments (5-40 mM) and collected at 24 hrs time 
interval. The images were captured using Olympus IX51 microscope (objective 
20x magnification) with scale bar of 200 µm. Healthy nuclei can be observed for 
5 mM glucose treatments. A significant amount of Shrunken/fragmented and 
pyknotic nuclei can be seen only under hyperglycemic conditions.  
 





     
    
Figure 4.9: Fluorescence microscopy for DAPI nuclear staining. Cells were 
subjected to different glucose treatments (5-40 mM) and collected at 48 hrs time 
interval. The images were captured using Olympus IX51 microscope (objective 
20x magnification) with scale bar of 200 µm. Healthy nuclei can be observed for 
5 mM glucose treatments. A significant amount of Shrunken/fragmented and 
pyknotic nuclei can be seen only under hyperglycemic conditions.  
 
 












Figure 4.10: Cell counting. Cells were subjected to different concentrations of 
glucose treatment (5-40 mM) and collected at 6-48 hrs time intervals. In each 
concentration of glucose treatment, the captured images of approximately 100 – 
120 cells were counted. The cells with shrunken, fragmented or pyknotic nuclei 
were considered as unhealthy nuclei and counted using image J software to 
identify the endothelial cell apoptosis. Each experiment was carried out in 
triplicate and as sets of three independent experiments (n=3). Data presented as 










Figure 4.11: Fluorescence microscopy for DAPI nuclear staining. Cells were 
subjected to different concentrations of glucose treatment (5-40 mM) and 
collected at 6-48 hrs time intervals. The images were captured using Olympus 
IX51 microscope (objective 20X magnification). Healthy nuclei can be observed 
for 5 mM glucose treatments. A significant amount of Shrunken/fragmented and 
pyknotic nuclei can be seen only under hyperglycemic conditions.  
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4.8 Fluorescence-activated cell sorting  
Since the hyperglycemic treatments of HUVECs significantly changed the nuclear 
morphology only at 24 and 48 hrs, a 3-dye staining followed by flow cytometry 
analysis was performed to further confirm that HUVECs undergo apoptosis 
during hyperglycemic treatments. The raw data was plotted as dot plot graph with 
Pacific blue - (DAPI stained cells) in the X-axis and Forward cell scatter - FCS 
(Cell size) in Y-axis. In the graphic representation, the healthy cells can be found 
to cluster in R6 quadrant whereas, in the R7 quadrant, an increase in the 
percentage of cells with shrunken nuclei (2.29, 10.37 and 13.24 % at 10, 25 and 
40 mM glucose respectively) after 24 hrs of incubation can be observed (Figure 
4.12). The percentage of cells with shrunken nuclei increased further (9.42, 12.34, 
15.34 % at 10, 25 and 40 mM glucose respectively) after 48 hrs of incubation 
(Figure 4.12).  
Furthermore, during apoptosis, cell surface exposes phosphatidylserine residues 
which can be labeled with Annexin V. Hence, the flow cytometry raw data for 
FCS-A Vs Alexa Fluor 488A (Annexin V staining) when plotted will specifically 
indicate the apoptotic cells only. The results showed an increase in apoptotic cells 
in R6 quadrant (15.07 & 19.91%) with a higher concentration of glucose 
treatment at 24hrs and 48hrs respectively (Figure 4.13).  
In order to differentiate necrosis from early and late apoptosis, the cells were 
examined after staining with PE-Texas Red-A (Homo dimer III stained cells) 
against cells stained with Alexa Fluor 488A (Annexin V stained cells). Figure 
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4.14 shows that the cells stained with annexin V remained only in R13 quadrant 
indicating that the cells were in the stage of early apoptosis. Quadrant R11 shows 
cells that were stained with both annexin V and homodimer III and hence they 
represented the cells in late apoptosis due to loss of their plasma membrane 
integrity. From all these results in Figures 4.12 – 4.14, it is also clear that the 
proportion of apoptotic cells increased with increasing glucose concentration as 
well as the time of exposure. 
 
Figure 4.12: Fluorescence activated cell sorting (FACS). HUVECs subjected to 
different concentrations of glucose treatment (5 mM, 10 mM, 25 mM and 40 mM 
glucose) for 24 and 48 hrs time intervals. In the FACS analysis, the cells were 
sorted out based on their size.  During hyperglycemic treatment cells will undergo 
cell shrinkage and the data were plotted as a dot-plot graph and the populations of 
healthy cells are gated in R6 whereas R7 quadrant cell population represents 
DAPI stained unhealthy cells with shrunken nuclei and fragmented nuclei. The 






Figure 4.13: Fluorescence activated cell sorting (FACS). HUVECs subjected to a 
different concentration of glucose treatment (5 mM, 10 mM, 25 mM and 40 mM 
glucose) for 24 and 48 hrs time interval. In the FACS analysis, the cell were 
sorted out based on positively stained cells (annexin-V an apoptotic marker),  and 
the data were plotted as a dot-plot graph and the populations of healthy cells are 
gated in R5 whereas R6 quadrant cell population represents annexin v stained 





Figure 4.14: Fluorescence activated cell sorting (FACS). HUVECs subjected to a 
different concentration of glucose treatment (5 mM, 10 mM, 25 mM and 40 mM 
glucose) for 24 and 48 hrs time interval. In the FACS analysis, the cell were 
sorted out based on the annexin-V and homodimer III apoptotic markers, and the 
data were plotted as a dot-plot graph and the populations of healthy cells are gated 
in R12 whereas R13 quadrant cell population represents annexin v stained early 
apoptotic cells and R11 represents annexin V and homodimer III stained late 








Figure 4.15: FACS Statistical analysis: The statistical analyses of FACS were 
represented in graph and each experiment was carried out in triplicate and as sets 
of three independent experiments (n=3). Data presented as mean ± SEM. * 
indicates statistical significance student – t-test, p < 0.05. 
112 
 
4.9 Hyperglycemia induced Caspase-3 mediated endothelial apoptosis 
Having examined endothelial apoptosis upon hyperglycemia, the 
molecular mechanism involved in the process of apoptosis was investigated. For 
this, both active caspase-3 protein level and caspase-3 activity were measured in 
the total cell lysates at different concentrations of glucose for 24 and 48 hrs. 
Compared to the control (5 mM glucose grown cells), treatment at 25 and 40 mM 
glucose showed a significant increase in the active form of caspase-3 protein that 
correlated well with its activity (on the substrate, DEVD-AMC). Moreover, both 
the caspase-3 protein and activity level increased further in 48 hrs time interval 
(Figure 4.15 and 4.16). But when these experiments were carried out in the 
presence of caspase 3 inhibitor (Ac-DEVD-CHO caspase3 inhibitor at 25 µM, 
from Alexis Biochemicals, NY, USA) neither active caspase 3 nor any apoptotic 
cells were detected. Moreover the MTT and LDH assay also showed that cell 
viability and cytotoxicity level were back to control 5 mM glucose treatment 
(Figure 4.18 and 4.19). Hence, from these results, we could interpret that 
hyperglycemia induced endothelial cell apoptosis is possibly mediated through a 





Figure 4.16: Measurement of Active caspase3. HUVECs subjected to a different 
concentration of glucose treatment (5 mM, 10 mM, 25 mM and 40 mM glucose) 
for 24 and 48 hrs time interval. Active Caspase 3 was measured by colorimetric 
readings. Each experiment was carried out in triplicate and in sets of three 
independent experiments (n=3). Data presented as mean ± SEM. * indicates 
statistical significance student – t-test, p < 0.05. 
  
Figure 4.17: Measurement of caspase3 activity. HUVECs subjected to a different 
concentration of glucose treatment (5 mM, 10 mM, 25 mM and 40 mM glucose) 
for 24 and 48 hrs time interval. Caspase 3 activity was measured by absorption of 
fluorescence released from the cleaved substrate (DEVD-AMC). Data presented 






Figure 4.18: Measurement of cell viability. HUVECs were treated with different 
concentration of glucose along with caspase 3 inhibitor to observe the cell 
viability. Each experiment was carried out in triplicates and in sets of three 
independent experiments (n=3). Data represented here are mean value ± SEM. * 




















Figure 4.19: Measurement of cytotoxicity. HUVECs were treated with different 
concentration of glucose along with caspase 3 inhibitor to measure the 
cytotoxicity. Each experiment was carried out in triplicates and in sets of three 
independent experiments (n=3). Data represented here are mean value ± SEM. * 









4.10 MicroRNAs as glucose sensors and possible indicators of endothelial 
dysfunction  
 
To understand the role of hyperglycemia induced endothelial dysfunction during 
T2DM, the shortlisted 62 miRNAs from HUVECs studies were compared with 
the commonly dysregulated 52 miRNAs during T2DM. The result showed that a 
total of 10 miRNAs gradually upregulated from IFG to T2DM with fold change ± 
1.2 and p<0.05 (Table 4.3). The shortlisted 10 miRNAs that responded to 
different glucose treatments (Figure 4.17) were then quantitated by stem loop 
PCR. The results confirmed that all the ten miRNAs were significantly 
upregulated at higher concentrations of glucose treatments at 24 hrs and 48 hrs 
respectively (Figure 4.18). From these, it can be interpreted that these miRNAs 























miR-26a-5p -1.64 1.80 1.40 1.27 1.55 1.84 2.12 
miR-26b-5p 2.37 1.52 1.33 1.23 1.42 1.44 2.24 
miR-29b-3p 1.45 1.96 2.02 1.69 2.19 2.42 2.86 
miR-29c-3p 1.55 2.35 2.45 1.86 2.21 2.65 3.25 
miR-125b-1-3p -1.55 1.70 2.23 1.27 1.97 1.41 4.30 
miR-130b-3p 1.87 1.89 1.54 1.11 1.22 1.27 1.57 
miR-140-5p 1.62 1.69 1.71 1.53 1.92 2.27 2.68 
miR-192-5p 1.34 2.25 1.87 1.45 1.87 1.97 2.41 
miR-221-3p 1.74 2.01 2.16 1.44 1.95 2.65 3.10 
miR-320a -1.58 1.81 2.87 1.59 1.90 1.81 2.46 
Table 4.3 Glucose-sensitive miRNAs observed in human and rat T2DM as well 
as in HUVECs upon hyperglycemic treatment. Fold change values with statistical 
significance (student t-test; p<0.05) in expression are shown below. The values 












Figure 4.20: miRNA expression in the microarray. The pattern of expression 
observed for the 10 selected miRNAs from the microarray data from HUVECs 
treated with different glucose treatments for 24 and 48 hrs. Each experiment was 
carried out in triplicate and in sets of three independent experiments (n=3). Data 


















Figure 4.21: Verification of microarray data by real-time quantitative PCR. Each 
experiment was carried out in triplicate and in sets of three independent 
experiments (n=3). Data presented as mean ± SEM. * indicates statistical 



































4.11 Correlation of selected miRNAs to their target mRNAs that are 
involved in endothelial apoptosis 
The above validated 10 miRNAs could be potentially involved in glucose 
mediated endothelial apoptosis. Hence, their target mRNAs have been traced 
using published data available from various laboratories (Table 4.4).  Among 
them six miRNAs, miR-26a-5p, -26b-5p, -29b-3p, -29c-3p, -192-5p and -320a are 
targeting anti-apoptotic genes MCL1 and BCL2 which could be directly involved 
in the caspase-3 mediated apoptosis pathway (Figures 4.19a&b and 4.20).  The 
real time quantitative PCR confirmed that the profiles of miRNAs and their 
corresponding target genes (MCL1 and BCL2) were opposite to one another 
indicating that these miRNAs can function as potential indicators of endothelial 
dysfunction associated apoptosis. In addition, to these, all the ten miRNAs also 
have additional validated targets genes (Table 4.4) and therefore they could 
participate in the regulation of other dysregulated pathways during hyperglycemia 











Gene description Gene Function 
miR-26a-5p 
HMGA2 
high mobility group AT-
hook 2[207] 
Down-regulation of HMGA2 promotes 
endothelial progenitor cell senescence[109] 
PTEN 
phosphatase and tensin 
homolog[208] 
Endothelial-specific deletion of PTEN 
prompts angiogenesis[209] and tumor 
growth[210] 
RB1 retinoblastoma 1[211] 
RB1 protects endothelial cell from 
apoptosis[211] and senescence[212] 
EZH2 
enhancer of zeste 2 
polycomb repressive 
complex 2 subunit[213] 
Decrease in EZH2 promotes endothelial 
cell to quiescence state,[214]  Gestational 
diabetes impairs HUVECs function via 
inhibition of EZH2[215] 
MCL1 myeloid cell leukemia 1[216] 
High expression of MCL1 induces tumor 
progression and angiogenesis[217] 
miR-26b-5p 
EPHA2  EPH receptor A2[218] 
Increased expression of EphA2 mediates 
vascular leakage [219] 
PTEN 
phosphatase and tensin 
homolog[220] 
Endothelial-specific deletion of PTEN 
prompts angiogenesis[209] and tumor 
growth[210] 
RB1 retinoblastoma 1[221] 
RB1 protects endothelial cell from 
apoptosis[211] and senescence[212] 
EZH2 
enhancer of zeste 2 
polycomb repressive 
complex 2 subunit[222] 
Decrease in EZH2 promotes endothelial 
cell to quiescence state[214],  Gestational 
diabetes impairs HUVECs function via 
inhibition of EZH2[215] 
MCL1 myeloid cell leukemia 1[223] 
High expression of MCL1 induces tumor 
progression and angiogenesis[217] 
miR-29b-3p 
MCL1 myeloid cell leukemia 1[224] 
High expression of MCL1 induces tumor 
progression and angiogenesis[217] 
BCL2 B-cell lymphoma 2[225] 
Decreases in BCL2 induces endothelial 
apoptosis[226] 
HDAC4 histone deacetylase 4[227] 
HDAC4 represses VEGFA expression by 
modulates RUNX2 activity[228] 
VEGFA 
vascular endothelial growth 
factor A[229] 
VEGFA induces pathological 
angiogenesis[230] 
PTEN 
phosphatase and tensin 
homolog[231] 
Endothelial-specific deletion of PTEN 
prompts angiogenesis[209] and tumor 
growth[210] 
miR-29c-3p 
MCL1 myeloid cell leukemia 1[232] 
High expression of MCL1 induces tumor 
progression and angiogenesis[217] 
BCL2   B-cell lymphoma 2[225] 
Decreases in BCL2 induces endothelial 
apoptosis[226] 
HDAC4 histone deacetylase 4[233] 
HDAC4 represses VEGFA expression by 
modulates RUNX2 activity[228] 
PTEN 
phosphatase and tensin 
homolog[234] 
Endothelial-specific deletion of PTEN 







Hyperglycemia induced decrease in 




 PTEN  
phosphatase and tensin 
homolog[237] 
Endothelial specific deletion of PTEN 
accelerates angiogenesis[209] and tumor 
growth[210] 
STAT3 
signal transducer and 
activator of transcription 
3[238] 
Interleukin 17 induces endothelial 
STAT3 mediated endothelial activation 





PPARG protects blood-brain barrier 
breakdown[242],  Disruption of endothelial 
PPARG induces atherogenesis [243] 
miR-140-5p 
VEGFA 
vascular endothelial growth 
factor A[229] 
VEGFA induces pathological 
angiogenesis[230] 
HDAC4 histone deacetylase 4[244] 
HDAC4 represses VEGFA expression by 
modulates RUNX2 activity[228] 
miR-192-5p 
BCL2 B-cell lymphoma 2[245] 
Decreases in BCL2 induces endothelial 
apoptosis[226] 
RB1 retinoblastoma 1[246] 
RB1 protects endothelial cell from 
apoptosis[211] and senescence[212] 
miR-221-3p 
PTEN 
phosphatase and tensin 
homolog[247] 
Endothelial specific deletion of PTEN 
accelerates angiogenesis[209] and tumor 
growth[210] 
RB1 retinoblastoma 1[248] 
RB1 protects endothelial cell from 
apoptosis[211] and senescence[212] 
PAK1 
p21 protein (Cdc42/Rac)-
activated kinase 1[249] 
PAK1 enhances endothelial barrier 







NRP1 promotes endothelial tip cell 
function during angiogenesis[253],  NRP1 
acts as the receptor for VEGFA and 
induces angiogenesis[254] 
MCL1 myeloid cell leukemia 1[255] 
High expression of MCL1 induces tumor 
progression and angiogenesis[217] 
Table 4.4: The ten selected miRNAs and their validated target mRNAs in the literature 
with potential functions related to endothelial dysfunction. The expression levels of 
miRNAs upon different glucose treatments are shown as fold changes normalized against 




Figure 4.22a: Quantitative real time PCR. The graph shows the correlation 
between miR-26a-5p, -26b-5p, 29b-3p, 29c-3p & 320a and its target MCL1 
mRNA. Data are presented as mean ± SEM (n=3). * indicates statistical 












Figure 4.22b: Quantitative real time PCR. The graph shows the correlation 
between miR-29b-2p, 29c-3p and -192-5p and its target BCL2 mRNA. Data are 





















Figure 4.23: A schematic representation of hyperglycemia induced endothelial 
apoptosis. High glucose induces down-regulation of antiapoptotic genes such as 
BCL2 and MCL1 via upregulation of various miRNAs and causes caspase-3 
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5. miRNAs in endothelial permeability 
5.1 Introduction: 
The primary function of an endothelium is to form a semipermeable mesh and 
maintain an effective barrier function. This allows essentially lower molecular 
weight molecules such as dissolved gases, ions, and glucose to pass through but 
not molecules like albumin, bacteria and white blood cells [256]. The barrier 
function of the endothelial monolayer is controlled by a wide range of biological, 
chemical, neural and mechanical stimuli. Barrier disruption often commences 
from compromised inter-endothelial junctions caused by endothelial 
hyperpermeability [181]. The major activators of endothelial hyperpermeability 
are vascular endothelial growth factor A (VEGFA), semaphorin 3A (SEMA3A), 
tumor necrosis factor (TNF-α), thrombin, bradykinin and histamine whereas 
signaling molecules such as sphingosine-1-phosphate receptor (S1PR) and 
angiopoeitin-1 are inhibitors of the process [257-262]. These signaling pathways 
potentially affect the endothelial adherens junction and tight junction proteins 
such as cadherin 5, type 2 (CDH5), Protein Tyrosine Phosphatase, Receptor Type, 
B (PTPRB), and platelet/endothelial cell adhesion molecule 1 (PECAM1) to bring 
about various vascular complications during diabetes and ischemic stroke [263, 
270]. The hyperglycemic condition in diabetes is the major risk factor that 
induces vascular permeability [268 - 272]. On the other hand, the current insulin 
treatment or diabetes-induced atherosclerosis and ischemic stroke could result in 
altered blood flow or blockage blood vessels that could cause hypoglycemia 
leading to an increase in endothelial permeability [270-272]. Hypoglycemia due 
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to diabetes drug treatment also plays a crucial role in vascular endothelial 
permeability due to impairment in VEGFA production [273, 274].  
5.2 in vitro model of endothelial permeability 
With the intention to study the hypo and hyperglycemia induced endothelial 
permeability, Human Umbilical Vein Endothelial Cells (HUVECs) were 
subjected to a different concentration of glucose treatment (0, 1, 5, 10, 25, & 40 
mM) and at various time intervals (6 hrs, 12 hrs, 24 hrs, and 48 hrs). Evan’s blue 
dye assay was performed to measure the endothelial permeability. The data from 
this study showed that both hypo and hyperglycemic conditions increased the 
endothelial permeability compared to their control (5mM) in a time dependent 






Figure 5.1: Evan’s blue dye assay: Human Umbilical Vein Endothelial Cells 
(HUVECs) were subjected to different concentrations of glucose and at 
different time intervals The Evan’s blue dye absorption was measured using 
nanodrop spectrophotometer at 600 nm. Each measurement was carried out in 
quadruplet and as three independent sets of experiments (n = 3). Data are 
presented as mean ± SEM. * indicates statistical significance student – t-test, p 
< 0.05.  
5.3 VEGFA in endothelial permeability 
VEGFA is well known as a potent endothelial permeability factor. Hence, the 
secretion of VEGFA was measured in the conditioned medium after respective 
hypo and hyperglycemic treatments and at various time intervals (6, 12, 24 & 48 
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hrs). The results showed that there was an increase in the level of VEGFA protein 
in the medium (Figure 5.2). 
 
Figure 5.2: Measurement of VEGFA secretion: Human Umbilical Vein 
Endothelial Cells (HUVECs) were subjected to different concentrations of 
glucose and at different time intervals. The VEGFA protein levels were 
measured using ELISA kit (n = 3). Data presented as mean ± SEM. * indicates 




5.4 miRNA profiling and K-means clustering analysis 
Total RNAs isolated from HUVECs subjected to both hypo and hyperglycemic 
treatments were subjected to miRNA microarray. Analysis of miRNA profile data 
began with normalization of a signal raw intensity value to endogenous controls. 
The miRNAs that exhibited a signal intensity >300 and significant at p<0.05, 
were taken into consideration. The hierarchical clustering analysis on these 
miRNAs showed 177 miRNAs were significantly dysregulated during hypo and 
hyperglycemic treatments in at least one-time point (6/12/24/48 hrs) and one of 
the glucose treatments (0/1/10/25/40 mM) (Figure 4.5). To identify the miRNAs 
that are possibly involved in the process of endothelial hyperpermeability, the 
miRNAs were subjected to K-means clustering using TIGR MeV (v4.9) software 
(http://www.tm4.org/mev.html) [275]. K-means clustering is the widely used, 
simplest method in cluster analysis. K-means clustering follows an easy way to 
classify the miRNAs data set through certain number of clusters. The main idea of 
clustering is to define K-means (5 mM glucose treatment). Each cluster shows 
miRNA expression in different concentration of glucose with respect to 5 mM 
glucose treatment (Control). The results indicated a pattern of gradual 
upregulation or downregulation of miRNAs during glucose treatments [268]. The 
clustering analysis method was based on average linkage and expressed as the 
Euclidean distance metric. In each time interval, there are about 20 clusters that 
showed a fold change of ±1.2. Moreover, these clusters also followed the pattern  
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of Evan’s blue dye assay and VEGFA secretion assay respectively (Figure 5.3 – 
5.6). 
 
Figure 5.3: K-means clustering-6 hrs: HUVECs were subjected to different 
concentrations of glucose (milli molar, shown on the top of the graph) at 6 hrs 
time interval and miRNA microarray was performed. K-means clustering was 
carried out based on average link and Euclidean distance metric. Each 
experiment was carried out in triplicate and in sets of three independent 
experiments (n=3). Data presented as mean ± SEM. * indicates statistical 
significance student – t-test, p < 0.05. 
 
0     1      5    10    25    40 0    1     5    10    25   40 
0     1      5    10    25   40 0    1     5    10    25    40 





Figure 5.4: K-means clustering-12 hrs: HUVECs were subjected to different 
concentrations of glucose (milli molar, shown on the top of the graph) at 12 hrs 
time point and miRNA microarray was performed. K-means clustering was 
performed based on average link and Euclidean distance metric. Each 
experiment was carried out in triplicate and in sets of three independent 
experiments (n=3). Data presented as mean ± SEM. * indicates statistical 
significance student – t-test, p < 0.05. 
 





Figure 5.5: K-means clustering-24 hrs: HUVECs were subjected to different 
concentrations of glucose (milli molar, shown on the top of the graph) at 24 
hrs time interval and miRNA microarray was performed. K-means clustering 
was carried out based on average link and Euclidean distance metric. Each 
experiment was carried out in triplicate and in sets of three independent 
experiments (n=3). Data presented as mean ± SEM. * indicates statistical 
significance student – t-test, p < 0.05. 




Figure 5.6: K-means clustering-48 hrs: HUVECs were subjected to different 
concentrations of glucose (milli molar, shown on the top of the graph) at 48 
hrs time point and miRNA microarray was performed. K-means clustering 
was carried out based on average link and Euclidean distance metric. Each 
experiment was carried out in triplicate and in sets of three independent 
experiments (n=3). Data presented as mean ± SEM. * indicates statistical 
significance student – t-test, p < 0.05. 




5.5 Dysregulated miRNAs during endothelial hyperpermeability 
The miRNAs that were found to be dysregulated across different glucose 
concentration and at different time intervals were selected and the pattern of their 
expression to Evan’s blue assay for hyperpermeability was examined (Figures 5.7 
& 5.8) 
 
Figure 5.7: Correlation of miRNAs and endothelial permeability (6 & 12 hrs): 
HUVECs were subjected to different concentrations of glucose at 6 and 12 hrs 
time intervals. miRNA expression correlating to Evan’s blue dye assay of 
endothelial hyperpermeability were matched. Each experiment was carried out in 
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triplicate and in sets of three independent experiments (n=3). Data presented as 
mean ± SEM. * indicates statistical significance student – t-test, p < 0.05. 
 
 
Figure 5.8: Correlation of miRNAs and endothelial permeability (24 & 48 hrs): 
HUVECs were subjected to different concentrations of glucose at 24 and 48 hrs 
time intervals. miRNA expression correlating to Evan’s blue dye assay of 
endothelial hyperpermeability were matched. Each experiment was carried out in 
triplicate and in sets of three independent experiments (n=3). Data presented as 




5.6 miRNAs targeting VEGFA and other related genes as possible 
regulators of endothelial hyperpermeability  
A total of 28 miRNAs that could target VEGFA gene’s 3’UTR has been reported 
in the literature [229].Of these, 25 miRNAs could be confirmed from the 
microarray studies carried out in the laboratory on the RNA samples of HUVECs 
subjected to hyperglycemic conditions. Among those 14 miRNAs could be 
detected as follows: a) 6 miRNAs across all time intervals b) 4 miRNAs at an 
early time point of 12 hrs and c) 4 miRNAs during the late time points of 24 and 
48hrs. In addition to the above 14 validated miRNAs that are known to target the 
3’UTR of VEGFA, this study has identified 3 new miRNAs that could target 
VEGFA. Although, endothelial permeability is considered to be mainly mediated 
by VEGFA gene function, in this study the other possible genes such as SEMA3A, 
VEPTP, PTPRB, PECAM1, S1PR1, and S1PR3 have been included. Hence, 




K-Means Cluster VEGFA VEPTP SEMA3A PTPRB PECAM1 
↓ miRNAs miR-185-5p miR-15a-5p miR-15a-5p miR-15a-5p miR-335-3p miR-921 
miR-15a-5p miR-299-3p miR-16-5p miR-16-5p miR-16-5p miR-519e-3p 
 miR-16-5p miR-324-5p miR-17-5p miR-17-5p miR-106b-5p miR-570-3p 
 miR-17-5p miR-339-5p miR-20b-5p miR-20b-5p miR-299-3p miR-889-3p 
 miR-20b-5p miR-423-3p miR-29b-3p miR-29b-3p 
 
miR-921 
 miR-29b-3p miR-503 miR-34b-3p miR-93-5p 
   miR-34b-3p miR-1290 miR-93-5p miR-106b-5p 
   miR-93-5p 
 
miR-106a-5p miR-107 
   miR-106a-5p ↑ miRNAs miR-106b-5p miR-149-5p 
   miR-106b-5p miR-325 miR-107 
    miR-107 miR-335-3p miR-126-3p 
    miR-126-3p miR-519e-3p miR-140-5p 
    miR-127-3p miR-570-3p miR-149-3p 
    miR-140-5p miR-889-3p miR-185-5p 
    miR-147a miR-921 miR-299-3p 
    miR-149-3p 
 
miR-339-5p 
    miR-149-5p 
 
miR-423-3p 
    miR-181a 
 
miR-503 
     
Table 5.1: miRNAs validated and/or predicted to target genes involved in 
endothelial permeability. The miRNAs showing differential expression 
(upregulated, ↑; downregulated, ↓) in k-means clustering were selected and 




5.7 miRNAs targeting VEGFA and endothelial permeability 
Seventeen miRNAs that have been reported to target VEGFA, have the capacity to 
also control endothelial permeability. Figure 5.9 – 5.26 show the correlation 
between miRNA expression and the Evan’s blue permeability assay.  
 
Figure 5.9: Correlation of miRNAs and endothelial permeability (12 hrs) 
HUVECs were subjected to different concentrations of glucose at 12 hrs time 
interval. miRNAs correlating with Evan’s blue dye assay of endothelial 
hyperpermeability are shown. Each experiment was carried out in triplicate and in 
sets of three independent experiments (n=3). Data presented as mean ± SEM. * 





Figure 5.10: Correlation of miRNAs and endothelial permeability (12 hrs) 
HUVECs were subjected to different concentrations of glucose at 12 hrs time 
interval. miRNAs correlating with Evan’s blue dye assay of endothelial 
hyperpermeability are shown. Each experiment was carried out in triplicate and in 
sets of three independent experiments (n=3). Data presented as mean ± SEM. * 
indicates statistical significance student – t-test, p < 0.05 
 
 
Figure 5.11: Correlation of miRNAs and endothelial permeability (12 hrs) 
HUVECs were subjected to different concentrations of glucose at 12 hrs time 
interval. miRNAs correlating with Evan’s blue dye assay of endothelial 
hyperpermeability are shown. Each experiment was carried out in triplicate and in 
sets of three independent experiments (n=3). Data presented as mean ± SEM. * 





Figure 5.12: Correlation of miRNAs and endothelial permeability (24 hrs) 
HUVECs were subjected to different concentrations of glucose at 24 hrs time 
intervals. miRNAs correlating with Evan’s blue dye assay of endothelial 
hyperpermeability are shown. Each experiment was carried out in triplicate and in 
sets of three independent experiments (n=3). Data presented as mean ± SEM. * 
indicates statistical significance student – t-test, p < 0.05 
 
 
Figure 5.13: Correlation of miRNAs and endothelial permeability (24 hrs) 
HUVECs were subjected to different concentrations of glucose at 24 hrs time 
intervals. miRNAs correlating with Evan’s blue dye assay of endothelial 
hyperpermeability are shown. Each experiment was carried out in triplicate and in 
sets of three independent experiments (n=3). Data presented as mean ± SEM. * 




Figure 5.14: Correlation of miRNAs and endothelial permeability (24 hrs) 
HUVECs were subjected to different concentrations of glucose at 24 hrs time 
intervals. miRNAs correlating with Evan’s blue dye assay of endothelial 
hyperpermeability are shown. Each experiment was carried out in triplicate and in 
sets of three independent experiments (n=3). Data presented as mean ± SEM. * 




Figure 5.15: Correlation of miRNAs and endothelial permeability (48 hrs) 
HUVECs were subjected to different concentrations of glucose at 48 hrs time 
intervals. miRNAs correlating with Evan’s blue dye assay of endothelial 
hyperpermeability are shown. Each experiment was carried out in triplicate and in 
sets of three independent experiments (n=3). Data presented as mean ± SEM. * 




Figure 5.16: Correlation of miRNAs and endothelial permeability (48 hrs) 
HUVECs were subjected to different concentrations of glucose at 48 hrs time 
intervals. miRNAs correlating with Evan’s blue dye assay of endothelial 
hyperpermeability are shown. Each experiment was carried out in triplicate and in 
sets of three independent experiments (n=3). Data presented as mean ± SEM. * 
indicates statistical significance student – t-test, p < 0.05 
 
 
Figure 5.17: Correlation of miRNAs and endothelial permeability (48 hrs) 
HUVECs were subjected to different concentrations of glucose at 48 hrs time 
intervals. miRNAs correlating with Evan’s blue dye assay of endothelial 
hyperpermeability are shown. Each experiment was carried out in triplicate and in 
sets of three independent experiments (n=3). Data presented as mean ± SEM. * 





Figure 5.18: Correlation of miRNAs with VEGFA secretion (12 hrs). HUVECs 
were subjected to different concentrations of glucose at 12 hrs time intervals. 
miRNAs correlating with VEGFA secretion were matched. Each experiment was 
carried out in triplicate and in sets of three independent experiments (n=3). Data 
presented as mean ± SEM. * indicates statistical significance student – t-test, p < 
0.05 
 
Figure 5.19: Correlation of miRNAs with VEGFA secretion (12 hrs). HUVECs 
were subjected to different concentrations of glucose at 12 hrs time intervals. 
miRNAs correlating with VEGFA secretion were matched. Each experiment was 
carried out in triplicate and in sets of three independent experiments (n=3). Data 






Figure 5.20: Correlation of miRNAs with VEGFA secretion (12 hrs). HUVECs 
were subjected to different concentrations of glucose at 12 hrs time intervals. 
miRNAs correlating with VEGFA secretion were matched. Each experiment was 
carried out in triplicate and in sets of three independent experiments (n=3). Data 




Figure 5.21: Correlation of miRNAs with VEGFA secretion (24 hrs). HUVECs 
were subjected to different concentrations of glucose at 24 hrs time intervals. 
miRNAs correlating with VEGFA secretion were matched. Each experiment was 
carried out in triplicate and in sets of three independent experiments (n=3). Data 






Figure 5.22: Correlation of miRNAs with VEGFA secretion (24 hrs). HUVECs 
were subjected to different concentrations of glucose at 24 hrs time intervals. 
miRNAs correlating with VEGFA secretion were matched. Each experiment was 
carried out in triplicate and in sets of three independent experiments (n=3). Data 




Figure 5.23: Correlation of miRNAs with VEGFA secretion (24 hrs). HUVECs 
were subjected to different concentrations of glucose at 24 hrs time intervals. 
miRNAs correlating with VEGFA secretion were matched. Each experiment was 
carried out in triplicate and in sets of three independent experiments (n=3). Data 





Figure 5.24: Correlation of miRNAs with VEGFA secretion (48 hrs). HUVECs 
were subjected to different concentrations of glucose at 48 hrs time intervals. 
miRNAs correlating with VEGFA secretion were matched. Each experiment was 
carried out in triplicate and in sets of three independent experiments (n=3). Data 




Figure 5.25: Correlation of miRNAs with VEGFA secretion (48 hrs). HUVECs 
were subjected to different concentrations of glucose at 48 hrs time intervals. 
miRNAs correlating with VEGFA secretion were matched. Each experiment was 
carried out in triplicate and in sets of three independent experiments (n=3). Data 






Figure 5.26: Correlation of miRNAs with VEGFA secretion (48 hrs). HUVECs 
were subjected to different concentrations of glucose at 48 hrs time intervals. 
miRNAs correlating with VEGFA secretion were matched. Each experiment was 
carried out in triplicate and in sets of three independent experiments (n=3). Data 
presented as mean ± SEM. * indicates statistical significance student – t-test, p < 
0.05 
 
5.8 Quantitative real time PCR 
Next the possible genes (mRNAs) involved in endothelial permeability during 
hypo and hyperglycemic treatments were measured using SYBR green 
quantitative real time PCR. The results showed that both hypo (1 mM) and 
hyperglycemic (25 mM) treatments upregulated (fold change) genes such as 
VEGFA, SEMA3A, and SIPR3 to 4.73, 2.54, 2.46 and 2.75, 1.91, 1.54 respectively 
when  compared to control, 5 mM glucose treatment at 24hrs time interval (Figure 
5.27). These genes were further upregulated to 6.73, 3.45, 3.57 and 3.93, 2.78, 
2.83 for 1 mM and 25 mM glucose treatments respectively when the treatment 
was prolonged up to 48 hrs (Figure 5.27). As a consequence of upregulation of 
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expression of the miRNAs, the corresponding genes involved in endothelial 
permeability such as tight/adherens junction and others (PECAM1, PTPRB and 
S1PR1) became downregulated upon hypo and hyperglycemic treatment at 24 hrs 
(Fold change -2.85, -4.36, -2.16 and -8.23, -2.55, -7.61 respectively) and got 




Figure 5.27: Quantitative real time PCR. The expression of genes (mRNAs) 
possibly involved in endothelial permeability during hypo and hyperglycemic 
treatments were measured after 24 hrs time interval. Each experiment was carried 
out in triplicate and in sets of three independent experiments (n=3). Data 





5.9 Endothelial senescence 
Senescence is a stress and cellular damage response which arrests the cell 
permanently from dividing into daughter cells. Endothelial senescence can be 
classified into two types, a) Replicative senescence, in which the cells stop 
entering stationary stage due to the progressive shortening of telomeric DNA and 
b) Oxidative senescence, where the cells get forced to undergo senescence by 
various insults such as intracellular oxidative stress and DNA damage [276]. In 
endothelial cells, the senescence phenomenon results in pro-inflammatory, pro-
atherosclerotic and prothrombotic [277] effects. In diabetes, hyperglycemia 
induced mitochondrial dysfunction and oxidative stress is the major factors for 
endothelial senescence and aging-related vascular diseases [278-281]. The studies 
on endothelial senescence and vascular aging are gaining increased recognition. 
However, the unavailability of standard non-invasive techniques to access the 
endothelial senescence hampers the study of vascular aging. Therefore identifying 





5.10 in vitro model of endothelial senescence and β-galactosidase staining 
In order to identify whether endothelial cells undergo senescence during 
hyperglycemic treatment, the cells were stained with senescence associated β-
galactosidase. The results indicate that hyperglycemia does induce endothelial 
senescence at 24 and 48 hrs (Figure 5.28). 
 
 
Figure 5.28: Endothelial senescence - β-galactosidase staining.  HUVECs were 
subjected to different concentrations of glucose at 24 and 48 hrs time intervals. 
The endothelial senescence was measured using β-galactosidase staining kit and 
the images were captured using Olympus IX51 microscope (objective 20x 
magnification). Each experiment was carried out in triplicate and in sets of three 
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independent experiments (n=3). Data presented as mean ± SEM. * indicates 
statistical significance student – t-test, p < 0.05. 
5.11 Quantification of β-galactosidase staining using nanodrop method 
Once images were captured, the cells were completely lysed using lysis buffer 
and dissolved in solubilization buffer. Using nanodrop spectrophotometer, the 
intensity of the dye was measured at an absorption wavelength of 640 nm. The 
results are shown in Figure 5.29. It is clear that the hyperglycemic treatments 
indeed increase the β-galactosidase activity at 24 and 48hrs for the 25 and 40 mM 
glucose treatments  
 
Figure 5.29: Quantification of the β-galactosidase end product. HUVECs were 
subjected to different concentrations of glucose at 24 and 48 hrs time intervals. 
The endothelial senescence was measured by quantification of the end product, β-
galactosidase at 640 nm. Each experiment was carried out in triplicate and in sets 
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of three independent experiments (n=3). Data presented as mean ± SEM. * 











6.1 Circulating miRNAs as the diagnostic biomarkers for IFG and T2DM 
miRNAs are well characterized, small non-coding RNA molecules that are 
encrypted in the genomes of most organisms. The discovery of miRNAs has 
introduced an additional level of complexity to the current knowledge and 
transformed the perception of gene regulation. Recent technologies such as AGO-
CLIP-seq and UV-CLIP-seq, as well as sophisticated bioinformatics tools, help to 
decipher the complex miRNA interactome and enriched our current knowledge on 
how miRNAs target broad spectrum of their target genes to regulate various 
biological processes such as glucose, lipid, and energy metabolism [282-284]. 
Furthermore, the global expression analysis reveals that dysregulation of miRNA 
level correlates with the initiation as well as the progression of various diseases, 
including T2DM [97, 119 and 285].  
The presence of miRNAs in the bloodstream is beneficial as intercellular 
communicators from one cell to another. This was first reported by Valadi in 2007 
[286]. From then onwards, the hormone-like property of circulating miRNAs 
opened up a fascinating possibility of miRNAs as extracellular signaling 
molecules and they can be much more specific than the hormones themselves 
with the potential to regulate a wide range of biological functions including 
various disease states [287]. So far, circulating miRNAs have been found in 
various biological fluids such as blood, plasma, serum, urine, saliva, milk and 
cerebrospinal fluid [288-294]. Therefore, the presence of miRNAs in several body 
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fluids could be useful as biomarkers for diseases such as T2DM [295]. The 
circulating miRNAs are reported to be stable in blood and even under harsh 
conditions such as an extreme change in pH, boiling and multiple freeze-thaw 
cycles. The circulating miRNAs are also protected from endonuclease activity by 
binding to AGO2 protein or packed in exosomes during circulation in blood [295, 
296]. 
6.2 miRNAs as indicators of disease progression in T2DM 
According to World Health Organization (WHO), the current golden standard 
makers to detect IFG (impaired fasting glucose) and T2DM (Type 2 Diabetes 
Mellitus) are fasting blood glucose and Hemoglobin A1c (HbA1c) levels in the 
blood [297]. Although HbA1c level offers greater sensitivity and specificity, the 
global long-term prospective studies reported that HbA1c levels vary among 
gender, race and ethnicity [298, 299]. Furthermore, the HbA1c measurement in 
the blood could also fluctuate due to various factors such as erythropoiesis, 
genetic and chemical alterations in hemoglobin, splenectomy, 
hemoglobinopathies and drugs such as large dosage of aspirin [300]. Therefore, 
circulating miRNAs could be used as prognostic biomarkers of disease 
progression. 
IFG and T2DM have been involved in the impairment of endothelial function 
such as imbalance in the nitric oxide production, vasodilation, and 
vasoconstriction, induction of pathological angiogenesis that ceases barrier 
function. All these functional alterations are predominantly triggered by the 
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changes in the peripheral metabolic changes resulting in hyperglycemia. 
Therefore, there is a need to identify the IFG and T2DM in the early stages to 
prevent its progression and development of diabetic related vascular 
complications. The main focus of this study is to recognize the potential miRNAs 
as diagnostic biomarkers of IFG and T2DM. The miRNA microarray profiling 
data analysis of IFG and T2DM patient samples and a rat model of T2DM showed 
that miRNAs were dysregulated and clearly indicated disease progression in IFG 
and T2DM (Chapter 3). There were a total of about 52 miRNAs that were 
commonly dysregulated in human and rat T2DM and these miRNAs could 
possibly be involved in the diabetes-related predisposition such as insulin 
secretion, insulin sensitivity, and resistance in peripheral tissues such as adipose 
tissues, skeletal muscles and vascular dysfunction and it could lead to both micro 
and macrovascular complications in the later stages of diabetes.  
6.3 miRNAs in prediabetes and type 2 diabetes mellitus 
Circulating miRNAs are found to dysregulated in prediabetes and T2DM.  
Karolina et al, [97] and Wang et al, [142] reported that miR-144 is upregulated in 
T2DM. In addition, to that Wang et al, also reported that miR-150, miR-191, and 
miR-320a are upregulated in plasma samples of T2DM compared to healthy 
individuals which are consistent with this study. In category 1, miR-29b&c have 
been found to be upregulated in both prediabetes and T2DM. Roggli et al, [301] 
reported that these two miRNAs are possibly involved in the impairment of 
glucose-induced insulin secretion in pancreatic–β cells and triggers apoptosis by 
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decreasing the level of antiapoptotic protein Mcl1 in prediabetic NOD mice 
model. The circulating miRNA profiling study in prediabetes by Parrizas et al, 
[302] identified that miR-192 remained upregulated in prediabetes and returned to 
baseline among the patients who underwent intensive treatment of prolonged 
exercise. Apart from these, global miRNA expression in T1DM, T2DM and GDM 
study by Collares et al, [147] revealed that miR-27a, miR-140-3p and miR-142-
3p became upregulated in T2DM to target mRNAs associated with diabetes 
pathogenesis. Moreover, hyperglycemia is the major hallmark for T2DM that 
leads to various vascular complications. In this study, expression of ten miRNAs 
(miR-26a-5p, miR-26b-5p, miR-29b-3p, miR-29c-3p, miR-125b-1-3p, miR-130b-
3p, miR-140-5p, miR-192-5p, miR-221-3p and miR-320a) has been found to be 
gradually upregulated from IFG towards T2DM. This indicates that these 
miRNAs could potentially be candidates for the diagnosis of T2DM in earlier 
stages (Chapter 4; Table 4.3).  
6.4 Pathways dysregulated during IFG and T2DM 
The human body mainly utilizes glucose as an energy source for the adequate 
function of our body with the synchronized action of many organs such as 
pancreas, liver, skeletal muscles and adipose tissues. The impairment of the 
function of these tissues/organs is instrumental for the development of 
hyperglycemia during diabetes [303]. Hyperglycemia is now recognized as a key 
factor to stimulate a large number of alterations in the cellular and molecular 
levels in the vascular tissues and induces apoptosis, which contributes to the 
157 
 
initiation of vascular complications in diabetes [304]. Excess of glucose 
(hyperglycemia) in the blood of diabetic individuals undergoes nonenzymatic 
glycosylation of proteins and lipids to interfere with their normal functions in the 
vasculature. One the other hand, it promotes the formation of advanced 
glycosylation end products [AGEs] and oxidative stress to provoke superoxide 
production and imbalance in redox system by causing mitochondrial dysfunction 
[305]. Hyperglycemia could affect a wide range of biological pathways and pave 
the way for the vascular complications in diabetes.  
According to American diabetic association, most of the vascular clinical 
complications occur during prediabetes and T2DM [306].  In this study, 52 
miRNAs have been found to be dysregulated in IFG (prediabetes) and T2DM. To 
understand the relationship between these 52 miRNAs, KEGG pathway analysis 
was carried out and top 10 pathways such as regulation of actin cytoskeleton, 
PI3K-Akt signaling pathway, focal adhesion, apoptosis, Wnt signaling pathway, 
neurotrophin signaling pathway, MAPK signaling pathway, TGF-beta signaling 
pathway, mTOR signaling pathway, and insulin signaling pathways have been 
found to be affected. Of these, the key processes affected in the vasculature due to 
these dysregulated pathways are endothelial apoptosis, hyperpermeability, and 





Figure 6.1: Pathways involved in endothelial dysfunction. Diagrammatic representation of affected pathways and their role in 
vascular dysfunction during diabetes.  
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6.5 Endothelial apoptosis in diabetes 
Endothelial dysfunction has been implicated in the pathogenesis of diabetes. In-
vitro studies showed that wide range of stimuli such as hyperglycemia, AGEs, 
oxidative stress can provoke endothelial apoptosis and it could be an important 
mediator which flagged the way for vascular leakage, inflammation, pathological 
angiogenesis and cell cycle arrest [307-310]. The relationships between various 
stimuli in diabetes and endothelial apoptosis are not completely understood 
despite extensive investigation. For example, whether endothelial apoptosis is a 
consequence or cause for all the metabolic dysregulation in diabetes could not be 
answered clearly. 
Apoptosis or programmed cell death is a biological process involved in the 
removal of unwanted or injured cells [311]. Apoptosis could be characterized by 
morphological changes such as cell actin cytoskeleton rearrangement, caspase3 
activation, cell shrinkage, nuclear condensation, chromosomal DNA 
fragmentation and formation of apoptotic bodies [312]. In this study, we observed 
that exposure of hyperglycemia could provoke all these above mentioned 
morphological changes at the cellular level and induced apoptosis. Actin, a central 
molecular component, acts as cellular stress sensor and plays a key role in the 
hyperglycemia programmed cell death in diabetic condition [313]. Numerous 
studies  have elucidated that hyperglycemia-induced oxidative stress, 
mitochondrial dysfunction, and actin cytoskeleton rearrangement acts upstream 
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and results in caspase activation in both intrinsic and extrinsic apoptotic pathways 
[314].  
6.6 Regulation of actin cytoskeleton and vascular dysfunction 
The actin cytoskeleton organization is a crucial sensor to rapidly communicate 
with the neighboring cells in response to the various external stimuli and tightly 
regulate the vascular function [315, 316]. Regulation of actin cytoskeleton 
pathway involves in diverse function of vascular biology such as cell structure 
maintenance, glucose uptake, insulin exocytosis, pathological angiogenesis and 
vascular permeability [317-319]. Small GTPases, Ras homolog family member A 
(RHOA), Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP 
binding protein Rac1) (RAC1) and Cell division cycle 42 (CDC42) are the master 
regulators of actin cytoskeleton signaling pathways have their ability to influence 
the gene expression and cytoskeleton reorganization are dysregulated greater than 
2 fold in the mRNA microarray data from patient’s blood samples [320]. RHOA 
and its target molecule Rho kinase (ROCK) highly increased in endothelial cells 
with glucose treatment and stimulate the impairment of retinal microvessels and 
also promote progression of diabetic nephropathy during diabetes [321 - 323].  
Both RhoA and its downstream target ROCK molecules could be directly targeted 
by miR-146a, but the down-regulation of this miRNA in both IFG and T2DM 
samples could aggravate the diabetic vascular complications [324].  Another 
important molecule in the Small GTPases is Rac1 and it is essential for normal 
vascular performance and endothelial cell specific Rac1 deficiency leads to 
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impaired vasodilation and mild hypertension [325]. The pharmacological 
inhibition/dominant negative expression of Rac1 showed that it is involved in the 
regulation of eNOS expression and NO bioavailability [326].  The miRNAs 
validated to directly target Rac1 3’UTR such as miR-142-3p, 194-5p and miR-
320a are consistently upregulated in both human T2DM and rat model of T2DM 
blood samples [327-329]. A third critical molecule in the Rho GTPase family 
Cdc42 regulates a variety of cytoskeletal dynamics and glucose-stimulated insulin 
secretion. Studies by Park et al, Liu et al, and Zhang et al, independently reported 
that Cdc42 could be modulated by miR-29 family, miR-185 and miR-221 
respectively. These three reported miRNAs are upregulated in blood samples of 
patients with prediabetes and diabetes [330, 331 and 249]. Furthermore, actin 
cytoskeleton pathways are involved in the regulation of vascular permeability and 
are often affected due to endothelial dysfunction in diabetes. Changes in the 
regulation of actin cytoskeleton result in disruption of tight junction and adherens 
junction proteins in the vasculature resulting in the failure of the endothelial 
barrier function [332].  
6.7 miRNAs involved in PI3K/Akt signaling 
Phosphatidyl Inositol 3 Kinase (PI3K) is fundamental for insulin-mediated 
glucose metabolism in the whole body of an organism and its impairment could 
lead to obesity, insulin resistance, and vascular impairment during diabetes [333, 
334]. A key downstream molecule in the insulin-dependent PI3K signaling is 
Akt/PKB and knockout of Akt2/PKBβ in muscle reduces glucose metabolism and 
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worsens hyperglycemia [335], whereas over activation of phosphorylated 
Akt/PKB during high glucose condition crosstalk with TGF-β signaling and 
promotes key events in the disease progression of diabetic nephropathy [336-
338]. Therefore, there is a need to fine tune the gene expression to regulate its 
disease condition and miRNAs could be the potential agents for such purpose. 
Kang et al, [339] reported that silencing of let7b could activate AKT2. miR-29 
family, miR-150, and miR-194 that could target AKT2 3’UTR [340 - 344] have 
also been found to be upregulated  in diabetic patients examined in this study. 
Moreover, the tumor suppressor gene PTEN is widely known as a negative 
regulator of PI3K/AKT signaling [345, 346].  Kurlawalla-Martinez et al, and 
Wijesekara et al, in 2005 independently reported that deletion of PTEN gene 
protects against hyperglycemia, insulin resistance and increases insulin sensitivity 
[347, 348]. Likewise, AKT has positive and negative effect in diabetes. Lin et al, 
[349] reported that loss of PTEN stimulates cytoskeleton reorganization 
exacerbates the progression of high fat diet induced diabetic nephropathy. On the 
other hand, studies by Xing et al, [350] supported that high glucose-induced 
phenotypic changes in podocytes can be prevented by PTEN. Loss of endothelial 
specific PTEN a tumor suppressor gene increases pathological angiogenesis and it 
could be the cause for diabetic retinopathy [209]. In this study a handful of 
miRNAs, miR-17-5p, miR-19b-3p, miR-26a-5p, miR-26b-5p, miR-29c-3p, miR-
106b-5p, miR-130b-3p, miR-144-5p, and miR-221-3p have been found to directly 
target PTEN mRNA 3’UTR and modulate its protein expression [351-357].  
163 
 
6.8 miRNAs in crosstalk with other pathways involved in endothelial 
dysfunction 
Expression of 32 miRNAs (Chapter 3; category 1: 15 upregulated & category 2: 
17 downregulated) has been found to dysregulated in prediabetes and that gets 
worse in the later stage of diabetes. Hence, these miRNAs could be useful in the 
identification of detect genes that they target and the pathways dysregulated by 
them. From this data, it is possible to understand the role of these miRNAs in 
endothelial dysfunction such as endothelial activation, inflammation, 
angiogenesis, hyper-permeability, senescence, and apoptosis. Gimbrone and his 
colleagues are the first ones to develop the concept of endothelial activation that 
paves the way for sequences of endothelial dysfunction [358]. Endothelial 
activation could be induced by shear stress due to changes in blood flow pattern 
and inflammatory genes such as IFN-γ, IL-6, IL-18 & TNF-α. These genes have 
been found to be upregulated in the human mRNA microarray studies [359]. 
Suarez et al, elegantly demonstrated the role of TNF-α in EC activation in 
patients with sepsis. In our study miR-17-3p has been found to be upregulated in 
both IFG and T2DM whereas its target mRNAs, E-selectin, and ICAM-1 
expression were downregulated and thus restraining endothelial cell activation 
[360]. Cheng et al, in 2013 showed the miR-146a represses NF-κB pathway by 
directly targeting HuR and promoting endothelial activation by suppressing nitric 
oxide production [361]. miR-146a is also known to target the 3’UTR of Kruppel - 
like factor 4 (KLF4) which has an anti-proliferative effect on vascular smooth 
muscle cells. The downregulation of these miRNA could induce inflammatory 
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pathway and participate in pathological angiogenesis. In turn, KLF4 could also 
suppress the miR-146a transcription by binding to its promoter region thereby it 
forms a negative feedback loop [362]. Likewise, miR-130b found to be up-
regulated in both IFG and T2DM could directly target peroxisome proliferator-
activated receptor γ (PPARγ). Hence, it has the potential to mediate cell 
proliferation and tumor angiogenesis [363] Upregulation of miR-106b could 
target β-TRCP2 and thereby increase SNAIL gene expression and promote 
endothelial migration during pathological angiogenesis. Semo et al, also 
supported this work and demonstrated that knocking out of miR-106b in ischemic 
mice showed impairment in the neovascularization [364, 365]. From these, it is 
clear that miRNAs dysregulated in an earlier stages of diabetes could activate 
endothelial dysfunction and lead the way for the disease progression.  
6.9 Glucose-responsive miRNAs and their role in diabetes-induced 
endothelial dysfunction 
Most of the pathways analyzed showed miRNAs that are related to vascular 
dysfunction caused by high glucose in diabetes [366]. Endothelial cells are the 
first layer of defense for the vasculature and their dysfunction could lead to 
various diabetic complications. Therefore in this study, when HUVECs were 
subjected to different concentrations of glucose at various time intervals and a 
reduction in endothelial proliferation, increase in cytotoxicity and induction of  
endothelial dysfunction could be observed. In the case of hyperglycemia-induced 
endothelial dysfunction, there was a total of about 62 miRNAs that could be 
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identified which showed a gradual upregulation at different concentration of 
glucose and various time intervals (Chapter 4; Table 4.1). Expression of miR-20b-
5p was found to be upregulated with an increase in glucose concentration at 6 and 
24 hrs time intervals. This could be correlated with genes involved in 
dysregulation of PI3K/Akt signaling. PI3K mediated phosphorylation of Akt acts 
as a central molecule in the signaling pathway and it mediates phosphorylation of 
p21 at threonine 145 to promote endothelial cell proliferation [367, 368]. The p21 
(CDKNA) is the family member of cyclin-dependent kinase inhibitors involved in 
the NO production in the endothelial cell to initiate an anti-apoptotic property 
through inhibition of caspase-3 activation [369]. In our study hyperglycemic 
treatment induces inhibition of cell proliferation as well as endothelial apoptosis 
and this phenomenon could be due to upregulation of miR-20b-5p that targets 
CDKN1A (p21) 3’UTR and inhibits its function [370].  Ephrin B4 of the receptor 
tyrosine kinase family is involved in the specification of venous endothelial cells. 
Homozygous deletion of EphB4 showed impairment in the morphogenesis of 
capillary beds and venous vessels. Hyperglycemia-induced miR-20b-5p targets 
EphB4 and thereby induces vein endothelial disruption [371-373]. Hypoxia-
inducing factor (HIF) alpha could mediate various vascular responses such as 
endothelial nitric oxide production, migration, and tumor angiogenesis. Loss of 
endothelial HIF-1α results in reduced NO production and it might be a target by 
miR-20b-5p [374, 375]. Endothelial cell undergoes pathological angiogenesis 
during diabetes such as diabetic retinopathy. CRIM1 is a novel cysteine-rich 
repeat protein, strongly upregulated in endothelial cells during capillary tube 
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formation and maintenance. Conditional knockdown of endothelial CRIM1 
expression causes delayed vessel expansion and decreased the density of blood 
vessels. miR-20b-5p upregulated in our study could inhibit CRIM1 gene 
expression and causes endothelial dysfunction under hyperglycemic condition but 
in patient’s blood samples their expression was downregulated and this 
discrepancy could be due to low level of expression in blood [376, 377]. 
Oxidative stress plays a central role in the progress of diabetic micro and 
macrovascular complications [378]. The overproduction of superoxide occurs due 
to glucose metabolism deficits and this increases reactive oxygen species in 
mitochondria [379]. Oxidative stress homeostasis in the cells is maintained by 
numerous enzymes of pro and antioxidant functions. Hence, failure in the balance 
of reactive oxygen species could be responsible for the development of 
endothelial dysfunction in diabetes [380]. PON1 gene belongs to paraoxonase 
(PON) family and it negatively regulates oxidative stress, inflammation, and 
atherosclerosis due to endothelial dysfunction [381 - 383]. Besler et al, identified 
the role of high-density lipoprotein (HDL) associated PON1 activity in the 
stimulation of NO production [384]. In addition to these, endothelial cell-specific 
knockdown of PON1 gene has been found to accelerate the endothelial 
senescence characteristic features [385]. All these anti-oxidative, anti-
inflammatory, anti-senescence and anti-atherogenic properties of PON1 could 
possibly be quenched by hyperglycemia-induced miR-616-3p by directly 




A total of 10 miRNAs (miR-26a-5p, miR-26b-5p, miR-29b-3p, miR-29c-3p, miR-
125b-1-3p, miR-130b-3p, miR-140-5p, miR-192-5p, miR-221-3p, and miR-320a) 
have been identified among the 62 miRNAs that correlated with gradual increase 
in glucose treatment in vitro. They also showed an increase in expression from 
prediabetes to T2DM. Each miRNA has been found to have multiple targets (eg. 
HMGA2, CCND2, CDK6, PTEN, EZH2, RB1, MCL1, and IL6) and each of these 
genes could also be targeted by multiple miRNAs.  Consistent with our findings, 
high glucose has been demonstrated to induce miR-26a-5p expression by Dey et 
al [386]. Furthermore, Chen et al, [387] found that miR-26a-5p increases glucose 
uptake and suggested that there is a positive feedback loop between increased 
extracellular glucose concentration and miR-26a-5p expression.  A previous study 
by Suh et al, [388] reported that up-regulation of miR-26a-5p increases 
cardiomyocyte apoptosis by increasing reactive oxygen species (ROS) 
production, which is one of the important mediator/ pathways for glucose-induced 
endothelial apoptosis.  Apart from these studies, Lezina et al, [389] and Zhang et 
al, [390] independently reported that p53 pathway regulates miR-26a-5p 
expression and induces apoptosis in cancer. In our in vitro study, we have also 
observed that treatment of HUVECs with increasing concentrations of glucose 
increased glucose uptake as well as miR-26a-5p expression. This indicates that 
miR-26a-5p may be considered as a potential glucose sensor and a surrogate 
biomarker for endothelial cell apoptosis. 
High Mobility Group A2 (HMGA2) gene single nucleotide polymorphism was 
reported to be highly associated with devastating microvascular complications in 
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T2DM. Downregulation of HMGA2 could inhibit cell proliferation and induce 
cellular apoptosis whereas overexpression of HMGA2 in cancerous condition 
inhibits p53 mediated mitochondrial apoptosis by interfering with the binding of 
p53 with anti-apoptotic BCL2. In this study also by MTT assay, we observed 
hyperglycemia could reduce cell proliferation and induce apoptosis possibly 
through upregulation of miR-26a-5p and downregulation of HMGA2. We have 
also noticed that MCL1 and BCL2 genes that are known to be crucial for the 
caspase 3 mediated apoptosis can be targeted by miR-26a-5p, miR-26b-5p, miR-
29b-3p, miR-29c-3p, miR-320a and miR-29b-3p, miR-29c-3p, miR-192-5p 
respectively (Chapter 4; Figure 4.22 a&b). An opposite profile between the 
expression of the miRNAs and their corresponding target genes (mRNAs) could 
be observed to indicate that these miRNAs can function as potential biomarkers of 
endothelial dysfunction associated apoptosis. Additionally, miR-26a-5p, miR-
130b-5p, miR-140-5p, and miR-221-3p could be potentially useful as “glucose 
sensors”. They exhibited a positive correlation to the endogenous glucose levels 
in both the in vivo (human and rat samples) and in vitro (Chapter 4; Table 4.3) 
The other three miRNAs (miR-130b-3p, miR-140-5p and miR-221-3p) could be 
triggering endothelial dysfunction via inflammation, pathological angiogenesis, 
hyperpermeability, apoptosis, and senescence since they have been validated to 





6.10 Potential applications of miRNAs in clinical settings 
The results of this study have demonstrated 7 miRNAs (miR-26b-5p, miR-29b-
3p, miR-29c-3p, miR-130b-3p, miR-140-5p, miR-192-5p and miR-221-3p) 
gradually upregulated upon hyperglycemic treatment as well as between patients 
with IFG and T2DM. In vitro studies also showed that these 7 miRNAs are 
involved in endothelial apoptosis and, therefore, these miRNAs could be potential 
diagnostic markers along with current HbA1c level for early identification of 
diabetic patients especially in their IFG stage. They can also be developed as 
potential therapeutic targets  to prevent the progression of vascular complications 
due to diabetes. 
Blood-based biomarkers are stable in circulation and hence can be accurately 
measured. Furthermore, the time interval required to measure the miRNA 
expression in blood is merely few hours compared to traditional blood-based 
biomarkers. In addition to the miRNAs as  biomarkers for disease progression, as 
mentioned earlier, they could be used as potential therapeutic targets. Anti or pre-
miRNAs could be delivered into the patient's blood for circulation and to regulate 
the pathological vascular complications such as diabetic retinopathy and diabetic 
nephropathy. The chemically modified,  locked nucleic acid (LNA
TM
) miRNAs 
could further enhance the stability of miRNAs and hence, could be easily 




6.11 Future prospects of the study 
In this study, the hyperglycemia induced miRNAs and their roles in the regulation 
of various biological pathways involved in the endothelial dysfunction have been 
elucidated. This study focused mainly on the endothelial apoptosis. Hence, high 
glucose mediated endothelial apoptosis via caspase3 dependent pathways was 
studied in a detailed manner with relevance to vascular complication in T2DM. 
Other endothelial dysfunctions such as endothelial hyperpermeability and 
senescence are yet to be thoroughly investigated.  
The study provided with a total of 10 miRNAs that are found to be glucose 
responsive in both in vivo and in vitro conditions. Among them, 6 miRNAs have 
been found to directly target antiapoptotic genes.  The function of the remaining 4 
miRNAs needs to be investigated  in detail to completely understand the 
hyperglycemia induced endothelial apoptosis. This study has also identified 14 
other miRNAs that are related to endothelial permeability and validation of their 
target genes by quantitative real-time PCR confirmed their relevance to 
endothelial permeability. VEGFA that functions as a  key signaling molecule 
responsible for endothelial permeability was found to be increased in the culture 
medium upon hyperglycemic treatment and the miRNAs targeting its 3’UTR have 
also been found to be dysregulated. As a further study, the genes that are possibly 
involved in the endothelial permeability such as SEMA3A, S1PR1 and S1PR3 
have to be cloned and their binding regions for selected miRNAs should be 
identified and verified using luciferase assays.  
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6.12 Conclusion  
In this study, hyperglycemia-induced expression of miRNAs and their roles in 
endothelial dysfunction have been investigated. The first section of the study 
examined the dysregulation of miRNAs in prediabetes and type 2 diabetes 
condition of both human and rat blood samples. Hyperglycemia could be the 
major issue in diabetes which results in the dysregulation of miRNA expression 
and causes endothelial dysfunction. The findings in this study highlighted that the 
miRNAs found in patients with prediabetes could also be found in T2DM patients 
but with a higher level of expression than in the prediabetic condition. The results 
were also found to be consistent with the rat model of type 2 diabetes. It was 
interesting to find that the bioinformatics prediction resulted with a top 10 
pathways that get dysregulated. They were found to be related to endothelial 
dysfunction and diabetes. mRNA microarray profiles from the patient samples 
also showed profiles that correlated with the dysregulated miRNAs. The studies 
on in vitro model of hyperglycemia-induced endothelial dysfunction explored the 
possibility of miRNAs in endothelial cell apoptosis. A pool of six miRNAs, miR-
26a-5p, miR-26b-5p, miR-29b-3p, miR-29c-3p, miR-192-5p and miR-320a were 
identified.  All these miRNAs are potential regulators of anti-apoptotic genes such 
as MCL1 and BCL2 that are implicated in hyperglycemia-induced caspase-3 
mediated endothelial apoptosis. Furthermore, these miRNAs have been found to 
be glucose responsive miRNAs. Hence, the identification of such miRNAs 
regulating glucose metabolism and acting as “glucose sensors” would be useful in 
the diagnosis of individuals before the onset of diabetes.  
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The study has also highlighted the miRNAs involved in endothelial dysfunction 
such as apoptosis, hyperpermeability, and senescence. Ten miRNAs (miR-26a-5p, 
miR-26b-5p, miR-29b-3p, miR-29c-3p, miR-125b-1-3p, miR-130b-3p, miR-140-
5p, miR-192-5p, miR-221-3p, and miR-320a) have been found to be consistent 
among in vitro and in vivo studies of diabetes. In addition to them, another 
seventeen miRNAs (miR-15a, miR-16-5p, miR-17-5p, miR-20b-5p, miR-29b-3p, 
miR-34b-3p, miR93-5p, miR-106a-5p, miR-106b-5p, miR-107, miR-126, miR-
140-5p, miR-147a, miR-185-5p, miR-299-3p miR-339-5p, and miR-503)  were 
identified using k-means clustering should also be investigated in detail. Among 
them miRNAs that target genes involved in endothelial permeability such as 
VEGFA, SEMA3A, S1PR1, S1PR3, PTPRB, and PECAM1 could be observed. 
Further studies by luciferase assay are needed to verify the mRNA: miRNA 
interactions. The effects of hyperglycemia on endothelial cell tight junction and 
adherens junction disruption can be visualized with pre- and anti-miRNAs 
treatments. These might be useful in reversing the detrimental effects of 
endothelial dysfunction.  
The final part of the study showed preliminary data on hyperglycemia-induced 
endothelial cell senescence. Few miRNAs that may be associated with the genes 
(CCND1, RB1, and PCNA) involved in the regulation of cell cycle arrest and 
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